Embodiments of the invention relate generally to systems, devices, and methods for stimulating nerves, and more specifically relate to system, devices, and methods for electrically stimulating peripheral nerve(s) to treat various disorders, as well as signal processing systems and methods for enhancing diagnostic and therapeutic protocols relating to the same.
A wide variety of modalities can be utilized to neuromodulate peripheral nerves. For example, electrical energy can be delivered transcutaneously or percutaneously via electrodes on the skin surface with neurostimulation systems to stimulate peripheral nerves, such as the median, radial, and/or ulnar nerves in the upper extremities; the tibial, saphenous, and/or peroneal nerve in the lower extremities; or the auricular vagus, tragus, trigeminal, occipital, or cranial nerves on the head or ear, as non-limiting examples. Stimulation of these nerves has been shown to provide therapeutic benefit across a variety of diseases, including but not limited to movement disorders (including but not limited to essential tremor, Parkinson's tremor, orthostatic tremor, and multiple sclerosis), urological disorders, gastrointestinal disorders, cardiac diseases, and inflammatory diseases, mood disorders (including but not limited to depression, bipolar disorder, dysthymia, and anxiety disorder), pain syndromes (including but not limited to migraines and other headaches, trigeminal neuralgia, fibromyalgia, complex regional pain syndrome), among others. A number of conditions, such as tremors, can be treated through some form of transcutaneous, percutaneous, or other implanted forms of peripheral nerve stimulation.
Systems with compact, ergonomic form factors are needed to enhance efficacy, compliance, and/or comfort when using non-invasive or wearable neuromodulation devices. In several embodiments, neuromodulation systems and methods are provided that enhance or inhibit nerve impulses and/or neurotransmission, and/or modulate excitability of nerves, neurons, neural circuitry, and/or other neuroanatomy that affects activation of nerves and/or neurons. For example, neuromodulation (e.g., neurostimulation) can include one or more of the following effects on neural tissue: depolarizing the neurons such that the neurons fire action potentials; hyperpolarizing the neurons to inhibit action potentials; depleting neuron ion stores to inhibit firing action potentials; altering with proprioceptive input; influencing muscle contractions; affecting changes in neurotransmitter release or uptake; and/or inhibiting firing.
In some embodiments, disclosed here is a wearable neurostimulation device for transcutaneously stimulating one or more peripheral nerves of a user. The device can include, for example, any number of a plurality of electrodes configured to generate electric stimulation signals; and one or more hardware processors configured to: measure a plurality of distinct electromagnetic characteristics across the at least two electrodes; determine a plurality of connection quality indicators based on the measured plurality of electromagnetic characteristics, said connection quality indicators corresponding to a degree of connection between the at least two of the plurality of electrodes and skin of the user; update the plurality of connection quality indicators over a time window based on repeated measurements of the plurality of electromagnetic characteristics within the time window; determine that at least one of the plurality of connection quality indicators crosses a threshold within the time window; and/or change an operating characteristic of the wearable neurostimulation device based on the determination that the at least one of the plurality of connection quality indicators has crossed the threshold within the time window.
In some embodiments, the one or more hardware processors are configured to reset the plurality of connection quality indicators for a new time window.
In some embodiments, the one or more hardware processors are configured to maintain therapy during the time window where at least one of the plurality of connection quality indicators indicate a weak connection and where at least one of the plurality of connection quality indicators has not crossed the threshold.
In some embodiments, the electromagnetic characteristic comprises impedance.
In some embodiments, electromagnetic characteristic comprises voltage mismatch.
In some embodiments, the electromagnetic characteristic comprises a pulse shape In some embodiments, the operating characteristic includes stimulation settings.
In some embodiments, changing the operating characteristic includes generating an alert.
In some embodiments, each of the plurality of electromagnetic characteristics is configured to enable an independent determination of the connection quality indicator.
In some embodiments, disclosed herein is a method for monitoring the connection quality of a neurostimulation device. The method can include, for example, any number of the following: measuring a plurality of distinct electromagnetic characteristics across the at least two electrodes; determining a plurality of connection quality indicators based on the measured plurality of electromagnetic characteristics, said connection quality indicators corresponding to a degree of connection between the at least two of the plurality of electrodes and skin of the user; updating the plurality of connection quality indicators over a time window based on repeated measurements of the plurality of electromagnetic characteristics within the time window; determining that at least one of the plurality of connection quality indicators crosses a threshold within the time window; and changing an operating characteristic of the wearable neurostimulation device based on the determination that the at least one of the plurality of connection quality indicators has crossed the threshold within the time window.
In some embodiments, the method includes resetting the plurality of connection quality indicators for a new time window.
In some embodiments, the method includes maintaining therapy during the time window where at least one of the plurality of connection quality indicators indicate a weak connection and where at least one of the plurality of connection quality indicators has not crossed the threshold.
In some embodiments, the electromagnetic characteristic comprises impedance.
In some embodiments, the electromagnetic characteristic comprises voltage mismatch.
In some embodiments, the electromagnetic characteristic comprises a pulse shape determination.
In some embodiments, the operating characteristic includes stimulation settings.
In some embodiments, the changing the operating characteristic includes generating an alert.
In some embodiments, each of the plurality of electromagnetic characteristics is configured to enable an independent determination of the connection quality indicator.
In some embodiments, also disclosed herein is a wearable neurostimulation device for transcutaneously stimulating one or more peripheral nerves of a user. The device can include, for example, any number of the following: a plurality of electrodes configured to generate electric stimulation signals; and one or more hardware processors configured to: determine an electromagnetic characteristic across at least two of the plurality of electrodes; determine a connection quality indicator, corresponding to connection between the at least two of the plurality of electrodes and skin of the user, based on the determined electromagnetic characteristic; and/or change an operating characteristic of the wearable neurostimulation device based on the determined connection quality indicator.
In some embodiments, the electromagnetic characteristic comprises impedance.
In some embodiments, the electromagnetic characteristic comprises voltage mismatch.
In some embodiments, the electromagnetic characteristic comprises a pulse shape determination.
In some embodiments, the operating characteristic includes stimulation settings.
In some embodiments, the changing the operating characteristic includes generating an alert.
In some embodiments, the one or more hardware processors is configured to determine a plurality of electromagnetic characteristics across the at least two electrodes.
In some embodiments, each of the plurality of electromagnetic characteristics is configured to enable an independent determination of the connection quality indicator.
In some embodiments, the one or more hardware processors is configured to determine a plurality of connection quality indicators based on the determined plurality of electromagnetic characteristics.
In some embodiments, the one or more hardware processors is configured to track the determined plurality of connection quality indicators over a time period.
In some embodiments, the operating characteristic is only changed when at least one of the determined plurality of connection quality indicators exceed a threshold over the time period.
In some embodiments, disclosed herein is a wearable neurostimulation device for transcutaneously stimulating one or more peripheral nerves of a user. The device can include, for example, any number of the following: a plurality of electrodes configured to generate electric stimulation signals; and one or more hardware processors configured to: determine a plurality of electromagnetic characteristics across at least two of the plurality of electrodes; determine a plurality of connection quality indicators, corresponding to connection between the at least two of the plurality of electrodes and skin of the user, from each of the determined electromagnetic characteristic; track the plurality of connection quality indicators over a time window; and/or change an operating characteristic of the wearable neurostimulation device based on the tracking of the plurality of connection quality indicators.
In some embodiments, the plurality of electrodes comprise dry electrodes.
In some embodiments, the plurality of electrodes comprise a hydrogel.
In some embodiments, the plurality of electromagnetic characteristics comprise one or more of: impedance, voltage mismatch, and pulse shape determination.
In some embodiments, the one or more hardware processors is configured to track the plurality of connection quality indicators over a time window by maintaining one or more counters.
In some embodiments, the one or more hardware processors is configured to track the plurality of connection quality indicators over a time window by maintaining only a single counter based on the plurality of connection quality indicators.
In some embodiments, the one or more hardware processors is configured to change the operating characteristic of the wearable neurostimulation device if the plurality of connection quality indicators exceeds a threshold over the time window.
In some embodiments, the one or more hardware processors is configured to weight the plurality of connection quality indicators.
In some embodiments, the one or more hardware processors is configured to generate an alert to the patient.
In some embodiments, the one or more hardware processors is configured to change the operating characteristic of the wearable neurostimulation device by discontinuing stimulation.
In some embodiments, disclosed herein is a method for monitoring the connection quality of a neurostimulation device, that can include, for example, any number of the following: positioning a plurality of electrodes of the neurostimulation device on a skin of a user; delivering electrical stimulation transcutaneously through the plurality of electrodes; determining a plurality of electromagnetic characteristics across at least two of the plurality of electrodes; determining a plurality of connection quality indicators, corresponding to connection between the at least two of the plurality of electrodes and the skin of the user; tracking the plurality of connection quality indicators over a time window; and/or changing an operating characteristic of the wearable neurostimulation device if the plurality of connection quality indicators exceeds a threshold over the time window.
In some embodiments, the method includes determining a plurality of electromagnetic characteristics comprises determining one or more of impedance, voltage mismatch, and pulse shape.
In some embodiments, tracking the plurality of connection quality indicators comprises maintaining at least one counter of connection quality over the time window based on the plurality of connection quality indicators.
In some embodiments, tracking the plurality of connection quality indicators comprises maintaining only a single counter of connection quality over the time window based on the plurality of connection quality indicators.
In some embodiments, the method includes initializing a value of the counter after the end of the time window.
In some embodiments, the method includes altering a value of the counter based on at least one of the plurality of connection quality indicators.
In some embodiments, changing the operating characteristic comprises discontinuing delivering the electrical stimulation, and/or modifying the delivered electrical stimulation.
In some embodiments, modifying the delivered electrical stimulation comprises changing one or more of the frequency, voltage, current, or duration of the stimulation.
In some embodiments, the method also includes alerting the user to an abnormality in the connection quality.
In some embodiments, disclosed herein is a wearable neuromodulation device for transcutaneously modulating one or more peripheral nerves of a user. The device can include, for example, any number of the following: a plurality of effectors configured to generate neuromodulation signals; and one or more hardware processors configured to: determine a characteristic across at least two of the plurality of effectors; determine a connection quality indicator, corresponding to connection between the at least two of the plurality of effectors and skin of the user, based on the determined characteristic; and/or change an operating characteristic of the wearable neuromodulation device based on the determined connection quality indicator.
In some embodiments, disclosed herein is a wearable neuromodulation device for transcutaneously modulating one or more peripheral nerves of a user. The device can include, for example, any number of the following: a plurality of effectors configured to generate neuromodulation signals; and one or more hardware processors configured to: determine a plurality of characteristic across at least two of the plurality of effectors; determine a plurality of connection quality indicators, corresponding to connection between the at least two of the plurality of effectors and skin of the user, from each of the determined electromagnetic characteristic; track the plurality of connection quality indicators over a time window; and/or change an operating characteristic of the wearable neuromodulation device based on the tracking of the plurality of connection quality indicators.
In some embodiments, disclosed herein is a wearable neuromodulation device for transcutaneously modulating one or more peripheral nerves of a user. The device can include, for example, any number of the following: a plurality of electrodes configured to generate electric stimulation signals; and one or more hardware processors configured to: measure one, two, three, four, five, or more distinct electromagnetic characteristics across the at least two electrodes; determine one, two, three, four, five, or more connection quality indicators based on the measured one or more electromagnetic characteristics, said connection quality indicators corresponding to a degree of connection between the at least two, three, four, five, or more of the plurality of electrodes and skin of the user; update the one, two, or more connection quality indicators over a time window based on repeated measurements of the one, two, three, four, five, or more electromagnetic characteristics within the time window; determine that one, two, three, four, five, or more of the connection quality indicators crosses a threshold within the time window; and/or change an operating characteristic of the wearable neurostimulation device based on the determination that the one, two, three, four, five, or more of the connection quality indicators has crossed the threshold within the time window.
In some embodiments, disclosed herein is a neuromodulation device according to any one of the embodiments described in the disclosure. A device can, in some embodiments, comprise, consist essentially of, consist of, and/or not comprise any number of features as disclosed herein.
In some embodiments, disclosed herein is a method for tracking one or more connection quality indicators according to any one of the embodiments described in the disclosure.
In some embodiments, disclosed herein is a method for changing an operating characteristic of a wearable neuromodulation device based on tracking of a plurality of connection quality indicators.
In several embodiments, the embodiments described herein that, for example, monitor the connection quality of a neuromodulation system can have one or more of the following advantages: (i) greater therapeutic benefit with less discomfort (e.g., such as from electrical discharge from open circuits); (ii) less current use (e.g., less power and improved battery life); (iii) decreased device error alerts and interruptions in therapy (and thus delays in completing a therapy session); (iv) increased likelihood of patient compliance due to the foregoing; and/or (v) improving the sensitivity in the determination of when to generate the alert and/or stop delivery of the electrical stimulation to balance the safety of users with efficacy and comfort.
In some of the embodiments described herein, one, several or all of the following features are not included: (i) sensors configured to assess patient motion and/or collect motion data, (ii) accelerometers, gyroscopes, magnetometers, inertial measurement units. and (iii) EMG or other muscle sensors. In some embodiments, systems and methods are not configured for, or are not placed on the upper arm and/or are not configured for neuromodulation on the skin surface of the forehead. In some embodiments, systems and methods are not configured to, or do not modulate descending (e.g., efferent) nerve pathways, and only modulate ascending (e.g., afferent) nerve pathways. In some embodiments, systems and methods are not configured to, or do not modulate nerves only on the ventral side of the wrist. In some embodiments, systems and methods do not include any implantable components. In some embodiments, systems and methods are not configured for percutaneous or subcutaneous stimulation, and are only configured for transcutaneous neuromodulation. In some embodiments, systems and methods are not configured for only neuromodulating, e.g., stimulating the ventral side of the wrist, rather some configurations may neuromodulate, e.g., deliver stimulation between two or more of the ventral, dorsal, and/or lateral sides of the wrist to target the medial nerve.
Several embodiments disclosed herein relate to systems and methods for neuromodulation, including for example devices configured for providing neurostimulation. The neuromodulation (e.g., neurostimulation) devices provided herein may be configured to stimulate peripheral nerves of a user. The devices may be configured to transcutaneously transmit one or more neuromodulation (e.g., neurostimulation) signals across the skin of the user. In many embodiments, the devices are wearable devices configured to be worn by a user. The user may be a human, another mammal, or other animal user. A neuromodulation (e.g., neurostimulation) system is also provided in several embodiments and includes signal processing systems and methods for enhancing diagnostic and therapeutic protocols relating to the same. In some embodiments, the neuromodulation (e.g., neurostimulation) device is configured to be wearable on an upper extremity of a user (e.g., a wrist, forearm, arm, and/or finger(s) of a user). In some embodiments, the device is configured to be wearable on a lower extremity (e.g., ankle, calf, knee, thigh, foot, and/or toes) of a user. In some embodiments, the device is configured to be wearable on the head or neck (e.g., forehead, ear, neck, nose, and/or tongue). In several embodiments, dampening or blocking of nerve impulses and/or neurotransmitters are provided. In some embodiments, nerve impulses and/or neurotransmitters are enhanced.
In some embodiments, the device is configured to be wearable on or proximate an ear of a user, including but not limited to auricular neuromodulation (e.g., neurostimulation) of the auricular branch of the vagus nerve, for example. The device could be unilateral or bilateral, including a single device or multiple devices connected with wires or wirelessly.
In some embodiments, the neuromodulation (e.g., neurostimulation) devices and methods disclosed herein generally rely on a robust connection with the skin of the user. In some embodiments, the electrode material conforms to the irregularities on the skin surface to ensure a robust and proper electrical connection. Conformance of the electrode to the skin surface can be affected by properties of the electrode, including but not limited to shape, thickness, material compliance (e.g., stiffness or durometer), and/or adhesion properties. Particularly, due to an application of electrical stimulation, an improper connection can result, for example, in current concentration that may make the device inoperable and/or may be harmful or painful to the user. For example, current concentrations can occur as an electrode lifts from the skin surface thus reducing the area of contact and, if current delivered by the device is held constant, increasing the current density. The connection quality may vary based on user movement. The connection state or quality between the skin and the effectors, e.g., electrode(s) may also depend on the type material used for the electrodes. In some instances, to improve the quality of user experience, especially for all day wear or multiple reapplications, the effectors, e.g., electrodes, may not include an adhesive hydrogel material. While an adhesive hydrogel layer can improve conformance with the skin, the stickiness of the hydrogel can be uncomfortable for the user or collect dust and debris during wear. This can sometimes increase the risk of poor connection quality. In some embodiments, the wearer is instructed to wet the wrist or electrodes with water, gel, lotion, or another conductive medium to improve the connection at the skin interface. Without a proper connection between the neuromodulation device and the user, the overall efficacy can be reduced in some embodiments due to improper delivery of electrical stimulation to the appropriate nerve targets or reduced adherence with the recommended usage due to discomfort or device errors (e.g., device not operating normally). Accordingly, some of the systems and methods described herein improve the efficacy of treatment by determining the connection quality between the device and the user. It has been observed that an increase in device errors may cause some users to not comply with their therapy regime due to either frustration with the device or possible reduction in therapeutic effect. Accordingly, in some embodiments, increased connection quality results in enhanced comfort for the user and reduce number of device disconnection errors, thus increasing compliance or adherence.
When the quality of the connection between the neuromodulation (e.g., neurostimulation) device and the user is poor, the device can be programmed to halt the stimulation to avoid improper delivery of electrical stimulation. The device can be further programmed to alert a user of the poor quality connection. However, there may be instances where false positives are generated. For example, connection may be poor only for a small time period while the user is moving and then stabilize. However, if alerts are constantly generated when the connection is poor, this may adversely affect user experience. Moreover, if the stimulation/modulation is halted every time when there is some indication of poor connection quality, it may reduce the efficacy of the treatment, and/or causes delays in completing a therapy session. Accordingly, the systems and methods described herein improve the sensitivity in the determination of when to generate the alert and/or stop delivery of the electrical stimulation to balance the safety of users with efficacy and comfort.
Neuromodulation Device
The device 100 can include two or more effectors, e.g. electrodes 102 for providing neurostimulation signals. In some instances, the device 100 is configured for transcutaneous use only and does not include any percutaneous or implantable components. In some embodiments, the electrodes can be dry electrodes. In some embodiments, water or gel can be applied to the dry electrode or skin to improve conductance. In some embodiments, the electrodes do not include any hydrogel material, adhesive, or the like. The electrodes 102 can also be used to determine a connection quality as discussed below.
The device 100 can further include stimulation circuitry 104 for generating signals that are applied through the electrode(s) 102. The signals can vary in frequency, phase, timing, amplitude, or offsets. The device 100 can also include power electronics 106 for providing power to the hardware components. For example, the power electronics 106 can include a battery.
The device 100 can include one or more hardware processors 108. The hardware processors 108 can include microcontrollers, digital signal processors, application specific integrated circuit (ASIC), a field programmable gate array (FPGA) or other programmable logic device, discrete gate or transistor logic, discrete hardware components, or any combination thereof designed to perform the functions described herein. In an embodiment, all of the processing discussed herein is performed by the hardware processor(s) 108. The memory 110 can store data specific to patient and rules as discussed below.
In the illustrated figure, the device 100 can include one or more sensors 112. As shown in the figure, the sensor(s) 112 may be optional. Sensors could include, for example, biomechanical sensors configured to, for example, measure motion, and/or bioelectrical sensors (e.g., EMG, EEG, and/or nerve conduction sensors). Sensors can include, for example, cardiac activity sensors (e.g., ECG, PPG), skin conductance sensors (e.g., galvanic skin response, electrodermal activity), and motion sensors (e.g., accelerometers, gyroscopes). The one or more sensors 102 may include an inertial measurement unit (IMU).
In some embodiments, the IMU can include one or more of a gyroscope, accelerometer, and magnetometer, which may also be used to determine connection quality. The IMU can be affixed or integrated with the neuromodulation (e.g., neurostimulation) device 100. In an embodiment, the IMU is an off the shelf component. In addition to its ordinary meaning, the IMU can also include specific components as discussed below. For example, the IMU can include one more sensors capable of collecting motion data. In an embodiment, the IMU includes an accelerometer. In some embodiments, the IMU can include multiple accelerometers to determine motion in multiple axes. Furthermore, the IMU can also include one or more gyroscopes and/or magnetometer in additional embodiments. Since the IMU can be integrated with the neurostimulation device 100, the IMU can generate data from its sensors responsive to motion, movement, or vibration felt by the device 100. Furthermore, when the device 100 with the integrated IMU is worn by a user, the IMU can enable detection of voluntary and/or involuntary motion of the user.
The device 100 can optionally include user interface components, such as a feedback generator 114 and a display 116. The display 116 can provide instructions or information to users relating to calibration or therapy. The display 116 can also provide alerts, such an indication of poor connection quality or band not connected. Alerts may also be provided using the feedback generator 114, which can provide haptic feedback to the user, such as upon initiation or termination of stimulation, for reminder alerts, to alert the user of a troubleshooting condition such as connection quality, to perform a tremor inducing activity to measure tremor motion, among others. Accordingly, the user interface components, such as the feedback generator 114 and the display 116 can provide audio, visual, and haptic feedback to the user.
Furthermore, the device 100 can include communications hardware 118 for wireless or wired communication between the device 100 and an external system, such as the user interface device discussed below. The communications hardware 118 can include an antenna. The communications hardware 118 can also include an Ethernet or data bus interface for wired communications.
While the illustrated figure shows several components of the device 100, some of these components are optional and not required in all embodiments of the device 100. In some embodiments, a system can include a diagnostic device or component that does not include neuromodulation functionality. The diagnostic device could be a companion wearable device connected wirelessly through a connected cloud server, and include, for example, sensors such as cardiac activity, skin conductance, and/or motion sensors as described elsewhere herein.
In some embodiments, the device 100 can also be configured to deliver one, two or more of the following: magnetic, vibrational, mechanical, thermal, ultrasonic, or other forms of stimulation instead of, or in addition to electrical stimulation. Such stimulation can be delivered via one, two, or more effectors in contact with, or proximate the skin surface of the patient. However, in some embodiments, the device is configured to only deliver electrical stimulation, and is not configured to deliver one or more of magnetic, vibrational, mechanical, thermal, ultrasonic, or other forms of stimulation.
Although several neurostimulation devices are described herein, in some embodiments nerves are modulated non-invasively to achieve neuro-inhibition. Neuro-inhibition can occur in a variety of ways, including but not limited to hyperpolarizing the neurons to inhibit action potentials and/or depleting neuron ion stores to inhibit firing action potentials. This can occur in some embodiments via, for example, anodal or cathodal stimulation, low frequency stimulation (e.g., less than about 5 Hz in some cases), or continuous or intermediate burst stimulation (e.g., theta burst stimulation). In some embodiments, the wearable devices have at least one implantable portion, which may be temporary or more long term. In many embodiments, the devices are entirely wearable and non-implantable.
User Interface Device
In additional embodiments, data acquired from the one or more sensors 102 is processed by a combination of the hardware processor(s) 108 and hardware processor(s) 152. In further embodiments, data collected from one or more sensors 102 is transmitted to the user interface device 150 with little or no processing performed by the hardware processors 108. In some embodiments, the user interface device 150 can include a remote server that processes data and transmits signals back to the device 100 (e.g., via the cloud).
Controller
Impedance Determination
The impedance determination process 200 can begin at block 202 with measuring impedance between any two electrodes of the neurostimulation device 100. The determination of impedance can indicate a presence of an open circuit. For example, when there is a poor connection between the electrodes and the skin, the impedance value may be high, corresponding to an open circuit. Such high impedance can result in an improper delivery of electrical stimulation, such as an increase in current density. Accordingly, the impedance measurement can be used to determine connection quality between the electrodes and the skin. In some instances, impedance can be measured for some or all pairs of the electrodes 102.
At block 204, the controller 160 can compare the measured impedance with an impedance threshold value. This threshold value might be stored in the memory 110. Based on the comparison, the controller 160 can determine connection quality between the electrodes and the skin of the patient. The impedance for a skin is generally about 4 kΩ. The threshold value can be a factor of the general skin impedance. Example values include about, at least about, or no more than about 8 kΩ, 20 kΩ, 40 kΩ, 50 kΩ, or about 100 kΩ, or ranges including any two of the foregoing values. In some instances, the threshold value is at least about 4 kΩ. If the comparison indicates an open circuit condition, the controller 160 can set connection quality to be low or poor. The connection quality can be a numeric indicator. The numeric indicator can represent a degree of quality of connection. In some instances, the connection quality can be a binary indicator, indicating true (1) or false (0) for whether the connection quality is good or bad. The connection quality can also be a textual indicator, such as “Band Not Connected.” The connection quality indicator can be used by the controller 160 to determine output conditions as discussed in more detail below with respect to
Pulse Shape Determination
The pulse shape determination process 300 can begin at block 302 with a transmission of a pulse having a particular shape across any two electrodes of the neurostimulation device 100. In some instances, the pulse shape can correspond to a positive pulse. In other instances, the pulse shape can correspond to a negative pulse. In other instances, the pulse shape can correspond to a positive and a negative pulse, with an interpulse interval. The pulse shape can also be gaussian or any other profile. The controller 160 can use predetermined pulse shapes stored in the memory 110. The controller 160 can cause the transmission of the pulse at block 302.
When the connection quality is poor, the pulse shape is distorted as it is transmitted across the electrodes. Higher distortion generally corresponds to poor quality connection. Accordingly, the controller 160 can determine the change in the profile of the pulse that was transmitted. In some instances, the change is determined based on the area under the curve of the received pulse. In some instances, the change is determined based on features of the pulse in the time domain, such pulse width or pulse amplitude. The change may also be determined based on a phase of the waveform. Further, the change may also be determined based on duration or time points of wave shape. The change can also be determined based on cross-correlation of the transmitted and received pulse or any other suitable signal processing techniques. In some instances, about or at least about 10%, 15%, 20%, 25%, 30%, or more change in pulse shape or pulse shape features is used as a threshold to determine connection quality indicator. Other values of thresholds can be used to adjust sensitivity.
Based on the change in pulse profile, the controller 160 can determine the connection quality between the electrodes and the skin at block 306. As discussed above, the connection quality can be a numeric, binary, or a textual indicator. The connection quality indicator can be used by the controller 160 to determine output conditions as discussed in more detail below with respect to
Voltage Mismatch Determination
In several embodiments, the pulse shape determination process 400 can begin at block 402 with a determination of voltage across any two electrodes of the neurostimulation device 100. In some instances, the controller 160 can test the voltage difference across two electrodes. The actual voltage measured can be a function of connection quality between the electrodes and skin. If the connection quality is good, the actual voltage measured will be close to the expected value. In contrast, for a poor quality connection the actual voltage may deviate from the expected value. Accordingly, the controller 160 can compare the measured voltage with the expected voltage at block 404. Example values of thresholds for the voltage difference include about 5 k mV, about 10 k mV, about 50 k mV, about 70 k mV, and about 100 k mV or more or less, or ranges including any two of the foregoing values.
Based on the comparison, the controller 160 can determine an indication of connection quality between the electrodes and the skin at block 406. In some instances, the controller 160 can use the voltage mismatch determination process 300 by itself to determine the connection quality indicator and control output conditions.
Connection Quality Indicator Determination
That is, at block 502, the controller 160 can measure an electromagnetic characteristic between two electrodes. The electromagnetic characteristic can include voltage mismatch, impedance determination, or pulse shape determination as discussed above. In some embodiments, the electromagnetic characteristic does not include one or more of voltage mismatch, impedance determination, or pulse shape determination. Other electromagnetic characteristics can include signal quality of delivered current, including but not limited to signal to noise ratio.
At block 504, the controller 160 can compare the measured electrode characteristic with an expected value. For example, the controller 160 can compare the measured values with stored thresholds to identify an open circuit, or pulse shape distortion, or voltage mismatch as discussed above.
Based on the comparison, the controller 160 can determine connection quality indicator between one of the electrodes and skin of the patient at block 506. As discussed above, the connection quality indicator can be a numeric, binary, or a textual indicator. The connection quality indicator can be used by the controller 160 to determine output conditions. Output conditions can include alerts and/or control of the neurostimulation device 100. Alerts can include haptic feedback, visual display, and halting stimulation. For example, output conditions can include halting the stimulation, changing a characteristic of the stimulation, or maintaining current stimulation treatment.
Accumulation Dissipation (AD) Determination
The controller 160 can use any of the processes 200, 300, or 400 discussed above individually or in combination to determine connection quality and control output conditions. However, changing an output condition based on the determination of the connection quality from one of the processes instantaneously or relative instantaneously can result in false alarms or unnecessarily high sensitivity to connection condition.
The AD determination 520 can use outputs from some or all of the processes described above as shown in
The output conditions can include, for example, generating an alert, changing neuromodulation (e.g., stimulation) properties, halting the neuromodulation (e.g., stimulation), or maintaining neuromodulation (e.g., stimulation). The time component will be described below with respect to
At block 522, the controller 160 can receive connection quality indicators from the one or more processes 200-400 discussed above. In some examples, as illustrated in block 524, the controller 160 can maintain one or more counters in the memory 110 corresponding to overall connection quality based on the received connection quality indicators from each of the processes shown in
In some instances, the controller 160 can maintain separate counters for each of the processes illustrated in
At block 526, the controller 160 can compare the one or more counters to respective one or more threshold. If a single counter is used, the controller 160 compares the single counter with the threshold. When the counter exceeds a threshold, the controller 160 can generate an output condition as shown in block 528. If multiple counters are used, such as a counter for each of the processes input, the controller 160 can compare each of these counters with its respective threshold value. In one example, if any one of the counters exceed their respective threshold, the controller 160 can generate an output condition as shown in block 508. If the counters are within their limits, the controller 160 can continue monitoring the connection quality. In some instances, the controller 160 can poll one or more processes discussed above in a loop at regular intervals. Further, in some examples, the processes can run in parallel and send an indication at regular intervals.
In some instances, the time window is 125 milliseconds, 250 milliseconds, or 500 milliseconds, or more or less. The one or more counters may be initialized to zero at the start of a new time period. The time window can also be continuous. Thus, in some instances, the counters are not initialized after any particular time and maintained throughout the therapy time. Furthermore, in some cases, the threshold count is 64. In other examples, the threshold count can be 128 or higher. In additional examples, the threshold count can be less than 64, between about 32 and 512, or about 32, 64, 128, 256, 512, or ranges including any two of the foregoing values. The users may also be able to set threshold count based on their preferences. Output condition can include changing properties of the stimulation (for example, frequency, voltage, current, duration); halting the stimulation, or generating an alert that can be visual, auditory, or haptic.
Thus, based on the AD determination 520, the controller 160 can adjust or tune when to change the output or operating condition of the neurostimulation device 100 to balance between safety and efficacy. The threshold counts, like threshold values discussed above, can be adjusted to change sensitivity. For example, increasing the threshold count can make the neurostimulation device 100 less sensitive to connection quality errors, while decreasing the threshold count can make the neurostimulation device 100 more sensitive to connection quality errors. In some instances, the threshold counts and values can be set externally by a hospital or manufacturer and can be updated remotely.
Terminology
When a feature or element is herein referred to as being “on” another feature or element, it can be directly on the other feature or element or intervening features and/or elements may also be present. In contrast, when a feature or element is referred to as being “directly on” another feature or element, there are no intervening features or elements present. It will also be understood that, when a feature or element is referred to as being “connected”, “attached” or “coupled” to another feature or element, it can be directly connected, attached or coupled to the other feature or element or intervening features or elements may be present. In contrast, when a feature or element is referred to as being “directly connected”, “directly attached” or “directly coupled” to another feature or element, there are no intervening features or elements present. Although described or shown with respect to one embodiment, the features and elements so described or shown can apply to other embodiments. References to a structure or feature that is disposed “adjacent” another feature may have portions that overlap or underlie the adjacent feature.
Terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. For example, as used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises” and/or “comprising.” when used in this specification, specify the presence of stated features, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, steps, operations, elements, components, and/or groups thereof. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items and may be abbreviated as “/”.
Spatially relative terms, such as “under”, “below”, “lower”, “over”, “upper” and the like, may be used herein for ease of description to describe one element or feature's relationship to another element(s) or feature(s) as illustrated in the figures. It will be understood that the spatially relative terms are intended to encompass different orientations of the device in use or operation in addition to the orientation depicted in the figures. For example, if a device in the figures is inverted, elements described as “under” or “beneath” other elements or features would then be oriented “over” the other elements or features. Thus, the exemplary term “under” can encompass both an orientation of over and under. The device may be otherwise oriented (rotated 90 degrees or at other orientations) and the spatially relative descriptors used herein interpreted accordingly. Similarly, the terms “upwardly”, “downwardly”, “vertical”, “horizontal” and the like are used herein for the purpose of explanation only unless specifically indicated otherwise.
Although the terms “first” and “second” may be used herein to describe various features/elements (including steps), these features/elements should not be limited by these terms, unless the context indicates otherwise. These terms may be used to distinguish one feature/element from another feature/element. Thus, a first feature/element discussed below could be termed a second feature/element, and similarly, a second feature/element discussed below could be termed a first feature/element without departing from the teachings of the present invention.
Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising” means various components can be co-jointly employed in the methods and articles (e.g., compositions and apparatuses including device and methods). For example, the term “comprising” will be understood to imply the inclusion of any stated elements or steps but not the exclusion of any other elements or steps.
As used herein in the specification and claims, including as used in the examples and unless otherwise expressly specified, all numbers may be read as if prefaced by the word “about” or “approximately.” even if the term does not expressly appear. The phrase “about” or “approximately” may be used when describing magnitude and/or position to indicate that the value and/or position described is within a reasonable expected range of values and/or positions. For example, a numeric value may have a value that is +/−0.1% of the stated value (or range of values), +/−1% of the stated value (or range of values), +/−2% of the stated value (or range of values), +/−5% of the stated value (or range of values), +/−10% of the stated value (or range of values), etc. Any numerical values given herein should also be understood to include about or approximately that value, unless the context indicates otherwise. For example, if the value “10” is disclosed, then “about 10” is also disclosed. Any numerical range recited herein is intended to include all sub-ranges subsumed therein. It is also understood that when a value is disclosed that “less than or equal to” the value, “greater than or equal to the value” and possible ranges between values are also disclosed, as appropriately understood by the skilled artisan. For example, if the value “X” is disclosed the “less than or equal to X” as well as “greater than or equal to X” (e.g., where X is a numerical value) is also disclosed. It is also understood that the throughout the application, data is provided in a number of different formats, and that this data, represents endpoints and starting points, and ranges for any combination of the data points. For example, if a particular data point “10” and a particular data point “15” are disclosed, it is understood that greater than, greater than or equal to, less than, less than or equal to, and equal to 10 and 15 are considered disclosed as well as between 10 and 15. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
Although various illustrative embodiments are described above, any of a number of changes may be made to various embodiments without departing from the scope of the invention as described by the claims. For example, the order in which various described method steps are performed may often be changed in alternative embodiments, and in other alternative embodiments one or more method steps may be skipped altogether. Optional features of various device and system embodiments may be included in some embodiments and not in others. Therefore, the foregoing description is provided primarily for exemplary purposes and should not be interpreted to limit the scope of the invention as it is set forth in the claims.
The examples and illustrations included herein show, by way of illustration and not of limitation, specific embodiments in which the subject matter may be practiced. As mentioned, other embodiments may be utilized and derived there from, such that structural and logical substitutions and changes may be made without departing from the scope of this disclosure. Such embodiments of the inventive subject matter may be referred to herein individually or collectively by the term “invention” merely for convenience and without intending to voluntarily limit the scope of this application to any single invention or inventive concept, if more than one is, in fact, disclosed. Thus, although specific embodiments have been illustrated and described herein, any arrangement calculated to achieve the same purpose may be substituted for the specific embodiments shown. This disclosure is intended to cover any and all adaptations or variations of various embodiments. Combinations of the above embodiments, and other embodiments not specifically described herein, will be apparent to those of skill in the art upon reviewing the above description. The methods disclosed herein include certain actions taken by a practitioner; however, they can also include any third-party instruction of those actions, either expressly or by implication. For example, actions such as “percutaneously stimulating an afferent peripheral nerve” includes “instructing the stimulation of an afferent peripheral nerve.”
This application claims the benefit under 35 U.S.C. § 119 (e) to U.S. Prov. App. No. 62/886,218 filed on Aug. 13, 2019, which is hereby incorporated by reference in its entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3204637 | Frank et al. | Sep 1965 | A |
| 3870051 | Brindley | Mar 1975 | A |
| 4103808 | Hallman et al. | Aug 1978 | A |
| 4300575 | Wilson | Nov 1981 | A |
| 4458696 | Larimore | Jul 1984 | A |
| 4461075 | Bailey | Jul 1984 | A |
| 4539996 | Engel | Sep 1985 | A |
| 4569351 | Tang | Feb 1986 | A |
| 4582049 | Ylvisaker | Apr 1986 | A |
| 4729377 | Granek et al. | Mar 1988 | A |
| 4739764 | Lue et al. | Apr 1988 | A |
| 4763659 | Dunseath, Jr. | Aug 1988 | A |
| 4771779 | Tanagho et al. | Sep 1988 | A |
| 4981146 | Bertolucci | Jan 1991 | A |
| 4982432 | Clark et al. | Jan 1991 | A |
| 4996987 | Petrofsky | Mar 1991 | A |
| 5003978 | Dunseath, Jr. | Apr 1991 | A |
| 5052391 | Silverstone et al. | Oct 1991 | A |
| 5070862 | Berlant | Dec 1991 | A |
| 5137507 | Park | Aug 1992 | A |
| 5330516 | Nathan | Jul 1994 | A |
| 5397338 | Grey et al. | Mar 1995 | A |
| 5514175 | Kim et al. | May 1996 | A |
| 5540235 | Wilson | Jul 1996 | A |
| 5562707 | Prochazka et al. | Oct 1996 | A |
| 5562717 | Tippey et al. | Oct 1996 | A |
| 5573011 | Felsing | Nov 1996 | A |
| 5575294 | Perry et al. | Nov 1996 | A |
| 5606968 | Mang | Mar 1997 | A |
| 5643173 | Welles | Jul 1997 | A |
| 5775331 | Raymond et al. | Jul 1998 | A |
| 5833709 | Rise et al. | Nov 1998 | A |
| 5833716 | Bar-Or et al. | Nov 1998 | A |
| 5899922 | Loos | May 1999 | A |
| 6016449 | Fischell et al. | Jan 2000 | A |
| 6076018 | Sturman et al. | Jun 2000 | A |
| 6081744 | Loos | Jun 2000 | A |
| 6161044 | Silverstone | Dec 2000 | A |
| 6178352 | Gruzdowich et al. | Jan 2001 | B1 |
| 6351674 | Silverstone | Feb 2002 | B2 |
| 6366813 | DiLorenzo | Apr 2002 | B1 |
| 6366814 | Boveja et al. | Apr 2002 | B1 |
| 6445955 | Michelson et al. | Sep 2002 | B1 |
| 6449512 | Boveja | Sep 2002 | B1 |
| 6453204 | Rhoads | Sep 2002 | B1 |
| 6505074 | Boveja et al. | Jan 2003 | B2 |
| 6546290 | Shloznikov | Apr 2003 | B1 |
| 6564103 | Fischer et al. | May 2003 | B2 |
| 6579270 | Sussman et al. | Jun 2003 | B2 |
| 6652449 | Gross et al. | Nov 2003 | B1 |
| 6678548 | Echauz et al. | Jan 2004 | B1 |
| 6701185 | Burnett et al. | Mar 2004 | B2 |
| 6704603 | Gesotti | Mar 2004 | B1 |
| 6731987 | McAdams et al. | May 2004 | B1 |
| 6735474 | Loeb et al. | May 2004 | B1 |
| 6735480 | Giuntoli et al. | May 2004 | B2 |
| 6788976 | Gesotti | Sep 2004 | B2 |
| 6819956 | DiLorenzo | Nov 2004 | B2 |
| 6829510 | Nathan et al. | Dec 2004 | B2 |
| 6836684 | Rijkhoff et al. | Dec 2004 | B1 |
| 6862480 | Cohen et al. | Mar 2005 | B2 |
| 6892098 | Ayal et al. | May 2005 | B2 |
| 6937905 | Carroll et al. | Aug 2005 | B2 |
| 6959215 | Gliner et al. | Oct 2005 | B2 |
| 6959216 | Faghri | Oct 2005 | B2 |
| 6988005 | McGraw et al. | Jan 2006 | B2 |
| 7010352 | Hogan | Mar 2006 | B2 |
| 7089061 | Grey | Aug 2006 | B2 |
| 7146220 | Dar et al. | Dec 2006 | B2 |
| 7162305 | Tong et al. | Jan 2007 | B2 |
| 7171266 | Gruzdowich et al. | Jan 2007 | B2 |
| 7177694 | Elbaum | Feb 2007 | B2 |
| 7177703 | Boveja et al. | Feb 2007 | B2 |
| 7209787 | DiLorenzo | Apr 2007 | B2 |
| 7228178 | Carroll et al. | Jun 2007 | B2 |
| 7231254 | DiLorenzo | Jun 2007 | B2 |
| 7236830 | Gliner | Jun 2007 | B2 |
| 7254444 | Moore et al. | Aug 2007 | B2 |
| 7277758 | DiLorenzo | Oct 2007 | B2 |
| 7324851 | DiLorenzo | Jan 2008 | B1 |
| 7326235 | Edwards | Feb 2008 | B2 |
| 7328068 | Spinelli et al. | Feb 2008 | B2 |
| 7349739 | Harry et al. | Mar 2008 | B2 |
| 7353064 | Gliner et al. | Apr 2008 | B2 |
| 7369896 | Gesotti | May 2008 | B2 |
| 7499747 | Kieval et al. | Mar 2009 | B2 |
| 7529582 | DiLorenzo | May 2009 | B1 |
| 7558610 | Odderson | Jul 2009 | B1 |
| 7636602 | Baru Fassio et al. | Dec 2009 | B2 |
| 7643880 | Tanagho et al. | Jan 2010 | B2 |
| 7643882 | Boston | Jan 2010 | B2 |
| 7647112 | Tracey et al. | Jan 2010 | B2 |
| 7650190 | Zhou et al. | Jan 2010 | B2 |
| 7657317 | Thacker et al. | Feb 2010 | B2 |
| 7742820 | Wyler et al. | Jun 2010 | B2 |
| 7761166 | Giftakis et al. | Jul 2010 | B2 |
| 7769464 | Gerber et al. | Aug 2010 | B2 |
| 7857771 | Alwan et al. | Dec 2010 | B2 |
| 7899527 | Yun et al. | Mar 2011 | B2 |
| 7899556 | Nathan et al. | Mar 2011 | B2 |
| 7917201 | Gozani et al. | Mar 2011 | B2 |
| 7930034 | Gerber | Apr 2011 | B2 |
| 7949403 | Palermo et al. | May 2011 | B2 |
| 7957814 | Goetz et al. | Jun 2011 | B2 |
| 7974696 | DiLorenzo | Jul 2011 | B1 |
| 7974698 | Tass et al. | Jul 2011 | B2 |
| 7991476 | Nachum | Aug 2011 | B2 |
| 7996088 | Marrosu et al. | Aug 2011 | B2 |
| 7998092 | Avni et al. | Aug 2011 | B2 |
| 8000796 | Tass et al. | Aug 2011 | B2 |
| 8025632 | Einarsson | Sep 2011 | B2 |
| 8046083 | Teganthoff et al. | Oct 2011 | B2 |
| 8075499 | Nathan et al. | Dec 2011 | B2 |
| 8086318 | Strother et al. | Dec 2011 | B2 |
| 8121694 | Molnar et al. | Feb 2012 | B2 |
| 8145316 | Deem et al. | Mar 2012 | B2 |
| 8165668 | Dacey, Jr. et al. | Apr 2012 | B2 |
| 8165685 | Knutson et al. | Apr 2012 | B1 |
| 8170658 | Dacey, Jr. et al. | May 2012 | B2 |
| 8175718 | Wahlgren et al. | May 2012 | B2 |
| 8187209 | Guiffrida et al. | May 2012 | B1 |
| 8190249 | Gharieb et al. | May 2012 | B1 |
| 8195287 | Dacey, Jr. et al. | Jun 2012 | B2 |
| 8209036 | Nathan et al. | Jun 2012 | B2 |
| 8219188 | Craig | Jul 2012 | B2 |
| 8233988 | Errico et al. | Jul 2012 | B2 |
| 8260439 | Diubaldi et al. | Sep 2012 | B2 |
| 8265763 | Fahey | Sep 2012 | B2 |
| 8301215 | Lee | Oct 2012 | B2 |
| 8306624 | Gerber et al. | Nov 2012 | B2 |
| 8308665 | Harry et al. | Nov 2012 | B2 |
| 8313443 | Tom | Nov 2012 | B2 |
| 8326432 | Kalisek | Dec 2012 | B2 |
| 8343026 | Gardiner et al. | Jan 2013 | B2 |
| 8364257 | Van Den Eerenbeemd et al. | Jan 2013 | B2 |
| 8374701 | Hyde et al. | Feb 2013 | B2 |
| 8380314 | Panken et al. | Feb 2013 | B2 |
| 8382688 | Dar et al. | Feb 2013 | B2 |
| 8391970 | Tracey et al. | Mar 2013 | B2 |
| 8396556 | Libbus et al. | Mar 2013 | B2 |
| 8406841 | Lin et al. | Mar 2013 | B2 |
| 8409116 | Wang et al. | Apr 2013 | B2 |
| 8412338 | Faltys | Apr 2013 | B2 |
| 8414507 | Asada | Apr 2013 | B2 |
| 8417351 | Kilger | Apr 2013 | B2 |
| 8428719 | Napadow | Apr 2013 | B2 |
| 8430805 | Burnett et al. | Apr 2013 | B2 |
| 8435166 | Burnett et al. | May 2013 | B2 |
| 8447411 | Skelton et al. | May 2013 | B2 |
| 8452410 | Emborg et al. | May 2013 | B2 |
| 8463374 | Hudson et al. | Jun 2013 | B2 |
| 8473064 | Castel et al. | Jun 2013 | B2 |
| 8548594 | Thimineur et al. | Oct 2013 | B2 |
| 8571687 | Libbus et al. | Oct 2013 | B2 |
| 8581731 | Purks et al. | Nov 2013 | B2 |
| 8583238 | Heldman et al. | Nov 2013 | B1 |
| 8588884 | Hegde et al. | Nov 2013 | B2 |
| 8588917 | Whitehurst et al. | Nov 2013 | B2 |
| 8608671 | Kinoshita et al. | Dec 2013 | B2 |
| 8626305 | Nielsen et al. | Jan 2014 | B2 |
| 8639342 | Possover | Jan 2014 | B2 |
| 8644904 | Chang et al. | Feb 2014 | B2 |
| 8644938 | Craggs | Feb 2014 | B2 |
| 8660656 | Moser et al. | Feb 2014 | B2 |
| 8666496 | Simon et al. | Mar 2014 | B2 |
| 8679038 | Giuffrida | Mar 2014 | B1 |
| 8682441 | De Ridder | Mar 2014 | B2 |
| 8688220 | Degiorgio et al. | Apr 2014 | B2 |
| 8694104 | Libbus et al. | Apr 2014 | B2 |
| 8694110 | Nathan et al. | Apr 2014 | B2 |
| 8702584 | Rigaux et al. | Apr 2014 | B2 |
| 8702629 | Giuffrida et al. | Apr 2014 | B2 |
| 8706241 | Firlik et al. | Apr 2014 | B2 |
| 8718780 | Lee | May 2014 | B2 |
| 8738143 | Tucker et al. | May 2014 | B2 |
| 8740825 | Ehrenreich et al. | Jun 2014 | B2 |
| 8744587 | Miesel et al. | Jun 2014 | B2 |
| 8755892 | Amurthur et al. | Jun 2014 | B2 |
| 8768452 | Gerber | Jul 2014 | B2 |
| 8788045 | Gross et al. | Jul 2014 | B2 |
| 8788049 | Lasko et al. | Jul 2014 | B2 |
| 8792977 | Kakei et al. | Jul 2014 | B2 |
| 8798698 | Kim et al. | Aug 2014 | B2 |
| 8821416 | Johansson et al. | Sep 2014 | B2 |
| 8825163 | Grill et al. | Sep 2014 | B2 |
| 8825165 | Possover | Sep 2014 | B2 |
| 8843201 | Heldman et al. | Sep 2014 | B1 |
| 8845494 | Whitall et al. | Sep 2014 | B2 |
| 8845557 | Giuffrida et al. | Sep 2014 | B1 |
| 8855775 | Leyde | Oct 2014 | B2 |
| 8862238 | Rahimi et al. | Oct 2014 | B2 |
| 8862247 | Schoendorf et al. | Oct 2014 | B2 |
| 8868177 | Simon et al. | Oct 2014 | B2 |
| 8874227 | Simon et al. | Oct 2014 | B2 |
| 8880175 | Simon | Nov 2014 | B2 |
| 8886321 | Rohrer et al. | Nov 2014 | B2 |
| 8892200 | Wagner et al. | Nov 2014 | B2 |
| 8897870 | De Ridder | Nov 2014 | B2 |
| 8903494 | Goldwasser et al. | Dec 2014 | B2 |
| 8920345 | Greenberg et al. | Dec 2014 | B2 |
| 8923970 | Bar-Yoseph et al. | Dec 2014 | B2 |
| 8948876 | Gozani et al. | Feb 2015 | B2 |
| 8961439 | Yang et al. | Feb 2015 | B2 |
| 8972017 | Dar et al. | Mar 2015 | B2 |
| 8989861 | Su et al. | Mar 2015 | B2 |
| 9002477 | Burnett | Apr 2015 | B2 |
| 9005102 | Burnett et al. | Apr 2015 | B2 |
| 9008781 | Ahmed | Apr 2015 | B2 |
| 9011310 | Ahmed | Apr 2015 | B2 |
| 9017273 | Burbank et al. | Apr 2015 | B2 |
| 9026216 | Rossi et al. | May 2015 | B2 |
| 9042988 | Dilorenzo | May 2015 | B2 |
| 9060747 | Salorio | Jun 2015 | B2 |
| 9089691 | Libbus et al. | Jul 2015 | B2 |
| 9095351 | Sachs et al. | Aug 2015 | B2 |
| 9095417 | Dar et al. | Aug 2015 | B2 |
| 9107614 | Halkias et al. | Aug 2015 | B2 |
| 9119964 | Marnfeldt | Sep 2015 | B2 |
| 9155885 | Wei et al. | Oct 2015 | B2 |
| 9155890 | Guntinas-Lichius et al. | Oct 2015 | B2 |
| 9162059 | Lindenthaler | Oct 2015 | B1 |
| 9168374 | Su | Oct 2015 | B2 |
| 9174045 | Simon et al. | Nov 2015 | B2 |
| 9186095 | Machado et al. | Nov 2015 | B2 |
| 9192763 | Gerber et al. | Nov 2015 | B2 |
| 9220431 | Holzhacker | Dec 2015 | B2 |
| 9220895 | Siff et al. | Dec 2015 | B2 |
| 9227056 | Heldman et al. | Jan 2016 | B1 |
| 9238137 | Einav et al. | Jan 2016 | B2 |
| 9238142 | Heldman et al. | Jan 2016 | B2 |
| 9242085 | Hershey et al. | Jan 2016 | B2 |
| 9248285 | Haessler | Feb 2016 | B2 |
| 9248286 | Simon et al. | Feb 2016 | B2 |
| 9248297 | Hoyer et al. | Feb 2016 | B2 |
| 9254382 | Ahmad et al. | Feb 2016 | B2 |
| 9259577 | Kaula et al. | Feb 2016 | B2 |
| 9265927 | Yonce et al. | Feb 2016 | B2 |
| 9282928 | Giffrida | Mar 2016 | B1 |
| 9289607 | Su et al. | Mar 2016 | B2 |
| 9301712 | McNames et al. | Apr 2016 | B2 |
| 9302046 | Giuffrida et al. | Apr 2016 | B1 |
| 9311686 | Roush et al. | Apr 2016 | B2 |
| 9314190 | Giuffrida et al. | Apr 2016 | B1 |
| 9314622 | Embrey et al. | Apr 2016 | B2 |
| 9332918 | Buckley et al. | May 2016 | B1 |
| 9339213 | Otsamo et al. | May 2016 | B2 |
| 9339641 | Rajguru et al. | May 2016 | B2 |
| 9345872 | Groteke | May 2016 | B2 |
| 9364657 | Kiani et al. | Jun 2016 | B2 |
| 9364672 | Marnfeldt | Jun 2016 | B2 |
| 9375570 | Kiani et al. | Jun 2016 | B2 |
| 9387338 | Burnett | Jul 2016 | B2 |
| 9393430 | Demers et al. | Jul 2016 | B2 |
| 9408683 | St. Anne et al. | Aug 2016 | B2 |
| 9414776 | Sillay et al. | Aug 2016 | B2 |
| 9415205 | Lasko et al. | Aug 2016 | B2 |
| 9452287 | Rosenbluth et al. | Sep 2016 | B2 |
| 9468753 | Fisher et al. | Oct 2016 | B2 |
| 9474898 | Gozani et al. | Oct 2016 | B2 |
| 9549872 | Chen et al. | Jan 2017 | B2 |
| 9581972 | Arrow et al. | Feb 2017 | B1 |
| 9586038 | Kosierkiewicz | Mar 2017 | B1 |
| 9589698 | Anhalt et al. | Mar 2017 | B2 |
| 9597509 | Hoffer et al. | Mar 2017 | B2 |
| 9610442 | Yoo et al. | Apr 2017 | B2 |
| 9610459 | Burnett et al. | Apr 2017 | B2 |
| 9615797 | John | Apr 2017 | B2 |
| 9630004 | Rajguru et al. | Apr 2017 | B2 |
| 9649486 | Holzhacker | May 2017 | B2 |
| 9656070 | Gozani et al. | May 2017 | B2 |
| 9669211 | Wijting et al. | Jun 2017 | B2 |
| 9675800 | Li et al. | Jun 2017 | B2 |
| 9675801 | Kong et al. | Jun 2017 | B2 |
| 9707393 | Hsueh et al. | Jul 2017 | B2 |
| 9731126 | Ferree et al. | Aug 2017 | B2 |
| 9757584 | Burnett | Sep 2017 | B2 |
| 9782584 | Cartledge et al. | Oct 2017 | B2 |
| 9802041 | Wong et al. | Oct 2017 | B2 |
| 9861283 | Giuffrida | Jan 2018 | B1 |
| 9877679 | Giuffrida | Jan 2018 | B1 |
| 9877680 | Giuffrida et al. | Jan 2018 | B1 |
| 9884179 | Bouton et al. | Feb 2018 | B2 |
| 9924899 | Pracar et al. | Mar 2018 | B2 |
| 9956395 | Bikson et al. | May 2018 | B2 |
| 9974478 | Brokaw et al. | May 2018 | B1 |
| 9980659 | Sadeghian-Motahar et al. | May 2018 | B2 |
| 9992918 | Watanabe et al. | Jun 2018 | B2 |
| 10004900 | Kent et al. | Jun 2018 | B2 |
| 10016600 | Creasey et al. | Jul 2018 | B2 |
| 10022545 | Giuffrida | Jul 2018 | B1 |
| 10028695 | Machado et al. | Jul 2018 | B2 |
| 10045740 | John | Aug 2018 | B2 |
| 10046161 | Biasiucci et al. | Aug 2018 | B2 |
| 10076656 | Dar et al. | Sep 2018 | B2 |
| 10080885 | Nathan et al. | Sep 2018 | B2 |
| 10112040 | Herb et al. | Oct 2018 | B2 |
| 10118035 | Perez et al. | Nov 2018 | B2 |
| 10130809 | Cartledge et al. | Nov 2018 | B2 |
| 10130810 | Ferree et al. | Nov 2018 | B2 |
| 10137025 | Fior et al. | Nov 2018 | B2 |
| 10173060 | Wong et al. | Jan 2019 | B2 |
| 10179238 | Wong et al. | Jan 2019 | B2 |
| 10213593 | Kaplan et al. | Feb 2019 | B2 |
| 10213602 | Ironi et al. | Feb 2019 | B2 |
| 10232174 | Simon et al. | Mar 2019 | B2 |
| 10252053 | Page et al. | Apr 2019 | B2 |
| 10285646 | Grant | May 2019 | B1 |
| 10286210 | Yoo | May 2019 | B2 |
| 10293159 | Kong et al. | May 2019 | B2 |
| 10335594 | Lin et al. | Jul 2019 | B2 |
| 10335595 | Ferree et al. | Jul 2019 | B2 |
| 10342977 | Raghunathan | Jul 2019 | B2 |
| 10398896 | Lin et al. | Sep 2019 | B2 |
| 10456573 | Feinstein et al. | Oct 2019 | B1 |
| 10463854 | Perez | Nov 2019 | B2 |
| 10500396 | Tamaki et al. | Dec 2019 | B2 |
| 10537732 | Nachum et al. | Jan 2020 | B2 |
| 10549093 | Wong et al. | Feb 2020 | B2 |
| 10556107 | Yoo et al. | Feb 2020 | B2 |
| 10561839 | Wong et al. | Feb 2020 | B2 |
| 10603482 | Hamner et al. | Mar 2020 | B2 |
| 10610114 | Buckley et al. | Apr 2020 | B2 |
| 10625074 | Rosenbluth et al. | Apr 2020 | B2 |
| 10632312 | Ziv | Apr 2020 | B2 |
| 10661082 | Kerselaers | May 2020 | B2 |
| 10722709 | Yoo et al. | Jul 2020 | B2 |
| 10765856 | Wong et al. | Sep 2020 | B2 |
| 10773079 | Keller et al. | Sep 2020 | B2 |
| 10780269 | Gozani et al. | Sep 2020 | B2 |
| 10786669 | Rajguru et al. | Sep 2020 | B2 |
| 10814130 | Wong et al. | Oct 2020 | B2 |
| 10814131 | Goldwasser et al. | Oct 2020 | B2 |
| 10835736 | Horter et al. | Nov 2020 | B2 |
| 10850090 | Rosenbluth et al. | Dec 2020 | B2 |
| 10870002 | Wybo et al. | Dec 2020 | B2 |
| 10905879 | Wong et al. | Feb 2021 | B2 |
| 10918853 | Creasey et al. | Feb 2021 | B2 |
| 10940311 | Gozani et al. | Mar 2021 | B2 |
| 10945879 | Black et al. | Mar 2021 | B2 |
| 10960207 | Wong et al. | Mar 2021 | B2 |
| 10967177 | Lee | Apr 2021 | B2 |
| 11026835 | Black et al. | Jun 2021 | B2 |
| 11033206 | Roh | Jun 2021 | B2 |
| 11033731 | Jeffery et al. | Jun 2021 | B2 |
| 11033736 | Edgerton et al. | Jun 2021 | B2 |
| 11058867 | Nathan et al. | Jul 2021 | B2 |
| 11077300 | McBride | Aug 2021 | B2 |
| 11077301 | Creasey et al. | Aug 2021 | B2 |
| 11103699 | Oppenheim et al. | Aug 2021 | B1 |
| 11141586 | Campean et al. | Oct 2021 | B2 |
| 11141587 | Campean et al. | Oct 2021 | B2 |
| 11160971 | Sharma et al. | Nov 2021 | B2 |
| 11213681 | Raghunathan | Jan 2022 | B2 |
| 11224742 | Burnett | Jan 2022 | B2 |
| 11247040 | Ferree et al. | Feb 2022 | B2 |
| 11247053 | Rajguru et al. | Feb 2022 | B2 |
| 11266836 | Charlesworth et al. | Mar 2022 | B2 |
| 11318307 | Kern et al. | May 2022 | B2 |
| 11331480 | Hamner et al. | May 2022 | B2 |
| 11338120 | Yun et al. | May 2022 | B2 |
| 11338128 | Lawson et al. | May 2022 | B2 |
| 11344722 | Wong et al. | May 2022 | B2 |
| 11357981 | Moaddeb et al. | Jun 2022 | B2 |
| 11389651 | Tamaki et al. | Jul 2022 | B2 |
| 11420052 | Doskocil et al. | Aug 2022 | B2 |
| 11484710 | Mantovani et al. | Nov 2022 | B2 |
| 11504530 | Herr et al. | Nov 2022 | B2 |
| 11517753 | Rhodes | Dec 2022 | B2 |
| 11534605 | Bouton et al. | Dec 2022 | B2 |
| 11590348 | Moaddeb et al. | Feb 2023 | B2 |
| 11596784 | Hamner et al. | Mar 2023 | B1 |
| 11596791 | Wong et al. | Mar 2023 | B2 |
| 11596792 | Campean et al. | Mar 2023 | B2 |
| 11628300 | Rajguru et al. | Apr 2023 | B2 |
| 11642513 | Sharma et al. | May 2023 | B2 |
| 11672981 | Jaasma et al. | Jun 2023 | B2 |
| 11766191 | Sharma et al. | Sep 2023 | B2 |
| 11833352 | Law et al. | Dec 2023 | B2 |
| 11839762 | Doskocil et al. | Dec 2023 | B2 |
| 11844943 | Rajguru et al. | Dec 2023 | B2 |
| 11857778 | Hamner et al. | Jan 2024 | B2 |
| 11872399 | Raghunathan | Jan 2024 | B2 |
| 11878166 | Colburn et al. | Jan 2024 | B2 |
| 11890468 | Yu | Feb 2024 | B1 |
| 11890469 | Moaddeb et al. | Feb 2024 | B2 |
| 11896824 | Doskocil | Feb 2024 | B2 |
| 11911604 | Sharma et al. | Feb 2024 | B2 |
| 11918806 | Wong et al. | Mar 2024 | B2 |
| 11975190 | Cho et al. | May 2024 | B2 |
| 11992685 | Kassiri Bidhendi et al. | May 2024 | B2 |
| 20010020177 | Gruzdowich et al. | Sep 2001 | A1 |
| 20020055761 | Mann et al. | May 2002 | A1 |
| 20020161415 | Cohen et al. | Oct 2002 | A1 |
| 20020165586 | Hill et al. | Nov 2002 | A1 |
| 20020177882 | DiLorenzo | Nov 2002 | A1 |
| 20030032992 | Thacker et al. | Feb 2003 | A1 |
| 20030045922 | Northrop | Mar 2003 | A1 |
| 20030088294 | Gesotti | May 2003 | A1 |
| 20030093098 | Heitzmann et al. | May 2003 | A1 |
| 20030149457 | Tcheng et al. | Aug 2003 | A1 |
| 20030181959 | Dobak, III | Sep 2003 | A1 |
| 20030187483 | Grey et al. | Oct 2003 | A1 |
| 20030195583 | Gruzdowich et al. | Oct 2003 | A1 |
| 20040015094 | Manabe et al. | Jan 2004 | A1 |
| 20040088025 | Gessotti | May 2004 | A1 |
| 20040093093 | Andrews | May 2004 | A1 |
| 20040102819 | Zou et al. | May 2004 | A1 |
| 20040127939 | Grey et al. | Jul 2004 | A1 |
| 20040133249 | Gesotti | Jul 2004 | A1 |
| 20040167588 | Bertolucci | Aug 2004 | A1 |
| 20040249416 | Yun et al. | Dec 2004 | A1 |
| 20040267331 | Koeneman et al. | Dec 2004 | A1 |
| 20050021103 | DiLorenzo | Jan 2005 | A1 |
| 20050055063 | Loeb et al. | Mar 2005 | A1 |
| 20050060009 | Geotz | Mar 2005 | A1 |
| 20050065553 | Ben Ezra et al. | Mar 2005 | A1 |
| 20050075502 | Shafer | Apr 2005 | A1 |
| 20050171576 | Williams et al. | Aug 2005 | A1 |
| 20050171577 | Cohen et al. | Aug 2005 | A1 |
| 20050182454 | Gharib et al. | Aug 2005 | A1 |
| 20050222626 | DiLorenzo | Oct 2005 | A1 |
| 20050234309 | Klapper | Oct 2005 | A1 |
| 20050240241 | Yun et al. | Oct 2005 | A1 |
| 20060015153 | Gliner et al. | Jan 2006 | A1 |
| 20060047326 | Wheeler | Mar 2006 | A1 |
| 20060052726 | Weisz et al. | Mar 2006 | A1 |
| 20060074450 | Boveja et al. | Apr 2006 | A1 |
| 20060095088 | De Ridder | May 2006 | A1 |
| 20060161218 | Danilov | Jul 2006 | A1 |
| 20060173509 | Lee et al. | Aug 2006 | A1 |
| 20060184059 | Jadidi | Aug 2006 | A1 |
| 20060217781 | John | Sep 2006 | A1 |
| 20060224191 | DiLorenzo | Oct 2006 | A1 |
| 20060229678 | Lee | Oct 2006 | A1 |
| 20060253167 | Kurtz et al. | Nov 2006 | A1 |
| 20060276853 | Tass | Dec 2006 | A1 |
| 20060293723 | Whitehurst et al. | Dec 2006 | A1 |
| 20070027486 | Armstrong | Feb 2007 | A1 |
| 20070073361 | Goren et al. | Mar 2007 | A1 |
| 20070123951 | Boston | May 2007 | A1 |
| 20070123952 | Strother et al. | May 2007 | A1 |
| 20070142862 | DiLorenzo | Jun 2007 | A1 |
| 20070156179 | Karashurov | Jul 2007 | A1 |
| 20070156182 | Castel et al. | Jul 2007 | A1 |
| 20070156183 | Rhodes | Jul 2007 | A1 |
| 20070156200 | Kornet et al. | Jul 2007 | A1 |
| 20070173899 | Levin et al. | Jul 2007 | A1 |
| 20070173903 | Goren et al. | Jul 2007 | A1 |
| 20070203533 | Goren et al. | Aug 2007 | A1 |
| 20070203534 | Tapper | Aug 2007 | A1 |
| 20070207193 | Zasler et al. | Sep 2007 | A1 |
| 20070249952 | Rubin et al. | Oct 2007 | A1 |
| 20070255319 | Greenberg | Nov 2007 | A1 |
| 20070276217 | Brown et al. | Nov 2007 | A1 |
| 20070282228 | Einav et al. | Dec 2007 | A1 |
| 20080004672 | Dalal et al. | Jan 2008 | A1 |
| 20080009772 | Tyler et al. | Jan 2008 | A1 |
| 20080021505 | Hastings et al. | Jan 2008 | A1 |
| 20080027507 | Bijelic et al. | Jan 2008 | A1 |
| 20080030170 | Dacuay et al. | Feb 2008 | A1 |
| 20080033259 | Manto et al. | Feb 2008 | A1 |
| 20080033504 | Bertolucci | Feb 2008 | A1 |
| 20080051839 | Libbus et al. | Feb 2008 | A1 |
| 20080051845 | Mentelos | Feb 2008 | A1 |
| 20080058773 | John | Mar 2008 | A1 |
| 20080058871 | Libbus et al. | Mar 2008 | A1 |
| 20080058893 | Noujokat | Mar 2008 | A1 |
| 20080097564 | Lathrop | Apr 2008 | A1 |
| 20080147146 | Wahlgren et al. | Jun 2008 | A1 |
| 20080177398 | Gross et al. | Jul 2008 | A1 |
| 20080195007 | Podrazhansky et al. | Aug 2008 | A1 |
| 20080208282 | Gelfand et al. | Aug 2008 | A1 |
| 20080208288 | Podrazhansky et al. | Aug 2008 | A1 |
| 20080216593 | Jacobsen et al. | Sep 2008 | A1 |
| 20080243204 | Uthman et al. | Oct 2008 | A1 |
| 20080288016 | Amurthur et al. | Nov 2008 | A1 |
| 20080300449 | Gerber et al. | Dec 2008 | A1 |
| 20080306325 | Burnett et al. | Dec 2008 | A1 |
| 20080312520 | Rowlandson et al. | Dec 2008 | A1 |
| 20090018609 | DiLorenzo | Jan 2009 | A1 |
| 20090076565 | Surwit | Mar 2009 | A1 |
| 20090082831 | Paul et al. | Mar 2009 | A1 |
| 20090099623 | Bentwich | Apr 2009 | A1 |
| 20090105785 | Wei et al. | Apr 2009 | A1 |
| 20090112133 | Deisseroth et al. | Apr 2009 | A1 |
| 20090157138 | Errico et al. | Jun 2009 | A1 |
| 20090187121 | Evans | Jul 2009 | A1 |
| 20090216294 | Ewing et al. | Aug 2009 | A1 |
| 20090222053 | Gaunt et al. | Sep 2009 | A1 |
| 20090247910 | Klapper | Oct 2009 | A1 |
| 20090249617 | Karicherla et al. | Oct 2009 | A1 |
| 20090299435 | Gliner et al. | Dec 2009 | A1 |
| 20090312690 | Kim et al. | Dec 2009 | A1 |
| 20090318986 | Alo et al. | Dec 2009 | A1 |
| 20090326595 | Brockway et al. | Dec 2009 | A1 |
| 20090326607 | Castel et al. | Dec 2009 | A1 |
| 20100004715 | Fahey | Jan 2010 | A1 |
| 20100010381 | Skelton et al. | Jan 2010 | A1 |
| 20100010383 | Skelton et al. | Jan 2010 | A1 |
| 20100010572 | Skelton et al. | Jan 2010 | A1 |
| 20100057154 | Dietrich et al. | Mar 2010 | A1 |
| 20100059722 | Copp-Howland et al. | Mar 2010 | A1 |
| 20100076533 | Dar et al. | Mar 2010 | A1 |
| 20100099963 | Kilger | Apr 2010 | A1 |
| 20100107657 | Vistakula | May 2010 | A1 |
| 20100125220 | Seong | May 2010 | A1 |
| 20100152817 | Gillbe | Jun 2010 | A1 |
| 20100168501 | Burnett et al. | Jul 2010 | A1 |
| 20100168604 | Echauz | Jul 2010 | A1 |
| 20100174342 | Boston et al. | Jul 2010 | A1 |
| 20100222630 | Mangrum et al. | Sep 2010 | A1 |
| 20100227330 | Fink et al. | Sep 2010 | A1 |
| 20100228180 | Jayes et al. | Sep 2010 | A1 |
| 20100249637 | Walter et al. | Sep 2010 | A1 |
| 20100292527 | Schneider et al. | Nov 2010 | A1 |
| 20100298905 | Simon | Nov 2010 | A1 |
| 20100324611 | Deming et al. | Dec 2010 | A1 |
| 20110004268 | Tcheng et al. | Jan 2011 | A1 |
| 20110009920 | Whitehurst et al. | Jan 2011 | A1 |
| 20110021899 | Arps et al. | Jan 2011 | A1 |
| 20110040204 | Ivorra et al. | Feb 2011 | A1 |
| 20110040288 | Eckstein et al. | Feb 2011 | A1 |
| 20110054358 | Kim et al. | Mar 2011 | A1 |
| 20110071590 | Mounaim et al. | Mar 2011 | A1 |
| 20110098780 | Graupe et al. | Apr 2011 | A1 |
| 20110112605 | Fahey | May 2011 | A1 |
| 20110118805 | Wei et al. | May 2011 | A1 |
| 20110125212 | Tyler | May 2011 | A1 |
| 20110137375 | McBride | Jun 2011 | A1 |
| 20110184489 | Nicolelis et al. | Jul 2011 | A1 |
| 20110196446 | Wu | Aug 2011 | A1 |
| 20110202107 | Sunagawa et al. | Aug 2011 | A1 |
| 20110208444 | Solinky | Aug 2011 | A1 |
| 20110213278 | Horak et al. | Sep 2011 | A1 |
| 20110224571 | Pascual-Leone et al. | Sep 2011 | A1 |
| 20110230701 | Simon et al. | Sep 2011 | A1 |
| 20110245734 | Wagner et al. | Oct 2011 | A1 |
| 20110250297 | Oronsky et al. | Oct 2011 | A1 |
| 20110282412 | Glukhovsky et al. | Nov 2011 | A1 |
| 20110288615 | Armstrong et al. | Nov 2011 | A1 |
| 20110301663 | Wang et al. | Dec 2011 | A1 |
| 20120010492 | Thramann et al. | Jan 2012 | A1 |
| 20120046535 | Lin et al. | Feb 2012 | A1 |
| 20120050298 | Hoffman | Mar 2012 | A1 |
| 20120053491 | Nathan et al. | Mar 2012 | A1 |
| 20120059298 | Hoffman et al. | Mar 2012 | A1 |
| 20120078319 | De Ridder | Mar 2012 | A1 |
| 20120088986 | David et al. | Apr 2012 | A1 |
| 20120092178 | Callsen et al. | Apr 2012 | A1 |
| 20120098493 | Budike | Apr 2012 | A1 |
| 20120101326 | Simon et al. | Apr 2012 | A1 |
| 20120109013 | Everett et al. | May 2012 | A1 |
| 20120136410 | Rezai et al. | May 2012 | A1 |
| 20120158094 | Kramer et al. | Jun 2012 | A1 |
| 20120184801 | Simon et al. | Jul 2012 | A1 |
| 20120185020 | Simon et al. | Jul 2012 | A1 |
| 20120211013 | Otis | Aug 2012 | A1 |
| 20120220812 | Mishelevich | Aug 2012 | A1 |
| 20120239112 | Muraoka | Sep 2012 | A1 |
| 20120245483 | Lundqvist | Sep 2012 | A1 |
| 20120259255 | Tomlinson et al. | Oct 2012 | A1 |
| 20120277621 | Gerber et al. | Nov 2012 | A1 |
| 20120289869 | Tyler | Nov 2012 | A1 |
| 20120290036 | Karamanoglu et al. | Nov 2012 | A1 |
| 20120302821 | Burnett | Nov 2012 | A1 |
| 20120310298 | Besio et al. | Dec 2012 | A1 |
| 20120310299 | Norbert et al. | Dec 2012 | A1 |
| 20120310303 | Popovic et al. | Dec 2012 | A1 |
| 20120330182 | Alberts et al. | Dec 2012 | A1 |
| 20130006322 | Tai | Jan 2013 | A1 |
| 20130035745 | Ahmed et al. | Feb 2013 | A1 |
| 20130053817 | Yun et al. | Feb 2013 | A1 |
| 20130060124 | Zietsma | Mar 2013 | A1 |
| 20130066388 | Bernhard et al. | Mar 2013 | A1 |
| 20130066395 | Simon et al. | Mar 2013 | A1 |
| 20130085317 | Feinstein | Apr 2013 | A1 |
| 20130090519 | Tass | Apr 2013 | A1 |
| 20130106684 | Weast et al. | May 2013 | A1 |
| 20130116606 | Cordo | May 2013 | A1 |
| 20130123568 | Hamilton et al. | May 2013 | A1 |
| 20130123666 | Giuffrida et al. | May 2013 | A1 |
| 20130131484 | Pernu | May 2013 | A1 |
| 20130131770 | Rezai | May 2013 | A1 |
| 20130158624 | Bain et al. | Jun 2013 | A1 |
| 20130158627 | Gozani et al. | Jun 2013 | A1 |
| 20130178765 | Mishelevich | Jul 2013 | A1 |
| 20130211471 | Libbus et al. | Aug 2013 | A1 |
| 20130231713 | De Ridder et al. | Sep 2013 | A1 |
| 20130236867 | Avni et al. | Sep 2013 | A1 |
| 20130238049 | Simon et al. | Sep 2013 | A1 |
| 20130245486 | Simon et al. | Sep 2013 | A1 |
| 20130245713 | Tass | Sep 2013 | A1 |
| 20130253299 | Weber et al. | Sep 2013 | A1 |
| 20130267759 | Jin | Oct 2013 | A1 |
| 20130281890 | Mishelevich | Oct 2013 | A1 |
| 20130289647 | Bhadra et al. | Oct 2013 | A1 |
| 20130296967 | Skaribas et al. | Nov 2013 | A1 |
| 20130297022 | Pathak | Nov 2013 | A1 |
| 20130331907 | Sumners et al. | Dec 2013 | A1 |
| 20130333094 | Rogers et al. | Dec 2013 | A1 |
| 20130338726 | Machado | Dec 2013 | A1 |
| 20140025059 | Kerr | Jan 2014 | A1 |
| 20140031605 | Schneider | Jan 2014 | A1 |
| 20140039573 | Jindra | Feb 2014 | A1 |
| 20140039575 | Bradley | Feb 2014 | A1 |
| 20140046423 | Rajguru et al. | Feb 2014 | A1 |
| 20140058189 | Stubbeman | Feb 2014 | A1 |
| 20140067003 | Vase et al. | Mar 2014 | A1 |
| 20140078694 | Wissmar | Mar 2014 | A1 |
| 20140081345 | Hershey | Mar 2014 | A1 |
| 20140094675 | Luna et al. | Apr 2014 | A1 |
| 20140094873 | Emborg et al. | Apr 2014 | A1 |
| 20140128939 | Embrey et al. | May 2014 | A1 |
| 20140132410 | Chang | May 2014 | A1 |
| 20140142654 | Simon et al. | May 2014 | A1 |
| 20140148872 | Goldwasser et al. | May 2014 | A1 |
| 20140148873 | Kirn | May 2014 | A1 |
| 20140163444 | Ingvarsson | Jun 2014 | A1 |
| 20140171834 | DeGoede et al. | Jun 2014 | A1 |
| 20140200573 | Deem et al. | Jul 2014 | A1 |
| 20140214119 | Greiner et al. | Jul 2014 | A1 |
| 20140228927 | Ahmad et al. | Aug 2014 | A1 |
| 20140236258 | Carroll et al. | Aug 2014 | A1 |
| 20140246628 | Anhalt et al. | Sep 2014 | A1 |
| 20140249452 | Marsh et al. | Sep 2014 | A1 |
| 20140257047 | Slliay et al. | Sep 2014 | A1 |
| 20140257129 | Choi et al. | Sep 2014 | A1 |
| 20140276194 | Osorio | Sep 2014 | A1 |
| 20140277220 | Brennan et al. | Sep 2014 | A1 |
| 20140296752 | Edgerton et al. | Oct 2014 | A1 |
| 20140296934 | Gozani et al. | Oct 2014 | A1 |
| 20140296935 | Ferree | Oct 2014 | A1 |
| 20140300490 | Kotz et al. | Oct 2014 | A1 |
| 20140309709 | Gozanl et al. | Oct 2014 | A1 |
| 20140316484 | Edgerton et al. | Oct 2014 | A1 |
| 20140324118 | Simon et al. | Oct 2014 | A1 |
| 20140330068 | Partsch et al. | Nov 2014 | A1 |
| 20140330335 | Errico et al. | Nov 2014 | A1 |
| 20140336003 | Franz et al. | Nov 2014 | A1 |
| 20140336722 | Rocon De Lima et al. | Nov 2014 | A1 |
| 20140343462 | Burnet | Nov 2014 | A1 |
| 20140350436 | Nathan et al. | Nov 2014 | A1 |
| 20140358040 | Kim et al. | Dec 2014 | A1 |
| 20140364678 | Harry et al. | Dec 2014 | A1 |
| 20150004656 | Tang et al. | Jan 2015 | A1 |
| 20150005852 | Hershey et al. | Jan 2015 | A1 |
| 20150012067 | Bradley et al. | Jan 2015 | A1 |
| 20150038886 | Snow | Feb 2015 | A1 |
| 20150042315 | Cen | Feb 2015 | A1 |
| 20150044656 | Eichhorn et al. | Feb 2015 | A1 |
| 20150057506 | Luna et al. | Feb 2015 | A1 |
| 20150073310 | Pracar et al. | Mar 2015 | A1 |
| 20150080979 | Lasko et al. | Mar 2015 | A1 |
| 20150100004 | Goldman et al. | Apr 2015 | A1 |
| 20150100104 | Kiani et al. | Apr 2015 | A1 |
| 20150100105 | Kiani et al. | Apr 2015 | A1 |
| 20150148866 | Bulsen et al. | May 2015 | A1 |
| 20150148878 | Yoo et al. | May 2015 | A1 |
| 20150157274 | Ghassemzadeh et al. | Jun 2015 | A1 |
| 20150164377 | Nathan et al. | Jun 2015 | A1 |
| 20150164401 | Toth et al. | Jun 2015 | A1 |
| 20150190085 | Nathan et al. | Jul 2015 | A1 |
| 20150190634 | Rezai et al. | Jul 2015 | A1 |
| 20150196767 | Zaghloul | Jul 2015 | A1 |
| 20150202444 | Franke et al. | Jul 2015 | A1 |
| 20150208955 | Smith | Jul 2015 | A1 |
| 20150216475 | Luna et al. | Aug 2015 | A1 |
| 20150230733 | Heo et al. | Aug 2015 | A1 |
| 20150230756 | Luna et al. | Aug 2015 | A1 |
| 20150277559 | Vescovi et al. | Oct 2015 | A1 |
| 20150297901 | Kockx | Oct 2015 | A1 |
| 20150321000 | Rosenbluth et al. | Nov 2015 | A1 |
| 20150335882 | Gross et al. | Nov 2015 | A1 |
| 20160001096 | Mishelevich | Jan 2016 | A1 |
| 20160008620 | Stubbeman | Jan 2016 | A1 |
| 20160016014 | Wagner et al. | Jan 2016 | A1 |
| 20160022987 | Zschaeck et al. | Jan 2016 | A1 |
| 20160022989 | Pfeifer | Jan 2016 | A1 |
| 20160038059 | Asada et al. | Feb 2016 | A1 |
| 20160045140 | Kitamura et al. | Feb 2016 | A1 |
| 20160089045 | Sadeghian-Motahar et al. | Mar 2016 | A1 |
| 20160106344 | Nazari | Apr 2016 | A1 |
| 20160120432 | Sridhar et al. | May 2016 | A1 |
| 20160121110 | Kent et al. | May 2016 | A1 |
| 20160128621 | Machado et al. | May 2016 | A1 |
| 20160129248 | Creasey et al. | May 2016 | A1 |
| 20160158542 | Ahmed | Jun 2016 | A1 |
| 20160158565 | Lee | Jun 2016 | A1 |
| 20160198998 | Rahimi et al. | Jul 2016 | A1 |
| 20160213924 | Coleman et al. | Jul 2016 | A1 |
| 20160220836 | Parks | Aug 2016 | A1 |
| 20160262685 | Wagner et al. | Sep 2016 | A1 |
| 20160263376 | Yoo et al. | Sep 2016 | A1 |
| 20160279435 | Hyde et al. | Sep 2016 | A1 |
| 20160287879 | Denison et al. | Oct 2016 | A1 |
| 20160039239 | Yoo et al. | Nov 2016 | A1 |
| 20160336722 | Taxter | Nov 2016 | A1 |
| 20160339239 | Yoo et al. | Nov 2016 | A1 |
| 20160361540 | Simon et al. | Dec 2016 | A9 |
| 20160375249 | Bonnet et al. | Dec 2016 | A1 |
| 20170014625 | Rosenbluth et al. | Jan 2017 | A1 |
| 20170027812 | Hyde et al. | Feb 2017 | A1 |
| 20170042467 | Herr et al. | Feb 2017 | A1 |
| 20170056238 | Yi et al. | Mar 2017 | A1 |
| 20170056643 | Herb et al. | Mar 2017 | A1 |
| 20170079597 | Horne | Mar 2017 | A1 |
| 20170080207 | Perez et al. | Mar 2017 | A1 |
| 20170095667 | Yakovlev | Apr 2017 | A1 |
| 20170113045 | Baldassano et al. | Apr 2017 | A1 |
| 20170157398 | Wong et al. | Jun 2017 | A1 |
| 20170165485 | Sullivan et al. | Jun 2017 | A1 |
| 20170132067 | Wong et al. | Aug 2017 | A1 |
| 20170224991 | Wingeier | Aug 2017 | A1 |
| 20170239415 | Hwang et al. | Aug 2017 | A1 |
| 20170246481 | Mishelevich | Aug 2017 | A1 |
| 20170266443 | Rajguru et al. | Sep 2017 | A1 |
| 20170274208 | Nagel et al. | Sep 2017 | A1 |
| 20170287146 | Pathak et al. | Oct 2017 | A1 |
| 20170312505 | Ahmed | Nov 2017 | A1 |
| 20170312512 | Creasey et al. | Nov 2017 | A1 |
| 20170312513 | Hershey et al. | Nov 2017 | A1 |
| 20170361093 | Yoo et al. | Dec 2017 | A1 |
| 20170368329 | Tyler et al. | Dec 2017 | A1 |
| 20180001086 | Bartholomew et al. | Jan 2018 | A1 |
| 20180001088 | Tass | Jan 2018 | A1 |
| 20180021576 | Wong et al. | Jan 2018 | A1 |
| 20180028841 | Konofagou et al. | Feb 2018 | A1 |
| 20180036535 | Wong et al. | Feb 2018 | A1 |
| 20180042654 | Ingvarsson et al. | Feb 2018 | A1 |
| 20180049676 | Griffiths et al. | Feb 2018 | A1 |
| 20180064344 | Nguyen | Mar 2018 | A1 |
| 20180064362 | Hennings et al. | Mar 2018 | A1 |
| 20180064944 | Grill et al. | Mar 2018 | A1 |
| 20180116546 | Pastoor et al. | May 2018 | A1 |
| 20180132757 | Kong et al. | May 2018 | A1 |
| 20180140842 | Olaighin et al. | May 2018 | A1 |
| 20180168905 | Goodall et al. | Jun 2018 | A1 |
| 20180169400 | Wong et al. | Jun 2018 | A1 |
| 20180214694 | Parramon | Aug 2018 | A1 |
| 20180221620 | Metzger | Aug 2018 | A1 |
| 20180235500 | Lee et al. | Aug 2018 | A1 |
| 20180236217 | Hamner et al. | Aug 2018 | A1 |
| 20180264263 | Rosenbluth et al. | Sep 2018 | A1 |
| 20180345020 | Ironi et al. | Dec 2018 | A1 |
| 20190001117 | Ben-David et al. | Jan 2019 | A1 |
| 20190001129 | Rosenbluth et al. | Jan 2019 | A1 |
| 20190001139 | Mishra et al. | Jan 2019 | A1 |
| 20190126047 | Kassiri Bidhendi et al. | May 2019 | A1 |
| 20190143098 | Kaplan et al. | May 2019 | A1 |
| 20190143111 | Hamner et al. | May 2019 | A1 |
| 20190143113 | Wong et al. | May 2019 | A1 |
| 20190167976 | Byers et al. | Jun 2019 | A1 |
| 20190269914 | Moaddeb et al. | Sep 2019 | A1 |
| 20190298998 | Coleman et al. | Oct 2019 | A1 |
| 20190321636 | Law et al. | Oct 2019 | A1 |
| 20190343462 | Grant | Nov 2019 | A1 |
| 20190374771 | Simon et al. | Dec 2019 | A1 |
| 20200023183 | Ollerenshaw et al. | Jan 2020 | A1 |
| 20200038654 | Doskocil et al. | Feb 2020 | A1 |
| 20200046968 | Herr et al. | Feb 2020 | A1 |
| 20200061378 | Ganguly et al. | Feb 2020 | A1 |
| 20200093400 | Hamner et al. | Mar 2020 | A1 |
| 20200139118 | John et al. | May 2020 | A1 |
| 20200147373 | Tamaki et al. | May 2020 | A1 |
| 20200155847 | Perez | May 2020 | A1 |
| 20200171269 | Hooper et al. | Jun 2020 | A1 |
| 20200171304 | Simon et al. | Jun 2020 | A1 |
| 20200179687 | Wong et al. | Jun 2020 | A1 |
| 20200197707 | Covalin | Jun 2020 | A1 |
| 20200215324 | Mantovani et al. | Jul 2020 | A1 |
| 20200221975 | Basta et al. | Jul 2020 | A1 |
| 20200254247 | Brezel et al. | Aug 2020 | A1 |
| 20200254251 | Wong et al. | Aug 2020 | A1 |
| 20200269046 | Page et al. | Aug 2020 | A1 |
| 20200276442 | Owen | Sep 2020 | A1 |
| 20200282201 | Doskocil | Sep 2020 | A1 |
| 20200289813 | Ito et al. | Sep 2020 | A1 |
| 20200289814 | Hamner et al. | Sep 2020 | A1 |
| 20200297999 | Pal | Sep 2020 | A1 |
| 20200316379 | Yoo et al. | Oct 2020 | A1 |
| 20200324104 | Labuschagne et al. | Oct 2020 | A1 |
| 20200338348 | Honeycutt et al. | Oct 2020 | A1 |
| 20200367775 | Buckley et al. | Nov 2020 | A1 |
| 20200405188 | Sharma et al. | Dec 2020 | A1 |
| 20200406022 | Sharma et al. | Dec 2020 | A1 |
| 20210016079 | Ekelem et al. | Jan 2021 | A1 |
| 20210031026 | Simon et al. | Feb 2021 | A1 |
| 20210031036 | Sharma et al. | Feb 2021 | A1 |
| 20210052883 | Wong et al. | Feb 2021 | A1 |
| 20210052897 | Bhadra et al. | Feb 2021 | A1 |
| 20210052900 | Pepin et al. | Feb 2021 | A1 |
| 20210060337 | Wybo et al. | Mar 2021 | A1 |
| 20210069507 | Gozani et al. | Mar 2021 | A1 |
| 20210100999 | Rosenbluth et al. | Apr 2021 | A1 |
| 20210101007 | Hamner et al. | Apr 2021 | A1 |
| 20210113834 | Wong et al. | Apr 2021 | A1 |
| 20210162212 | Kern et al. | Jun 2021 | A1 |
| 20210169684 | Black et al. | Jun 2021 | A1 |
| 20210187279 | Bouton et al. | Jun 2021 | A1 |
| 20210205619 | Wong et al. | Jul 2021 | A1 |
| 20210213283 | Yoo et al. | Jul 2021 | A1 |
| 20210220650 | Kassiri Bidhendi et al. | Jul 2021 | A1 |
| 20210244940 | Liberatore et al. | Aug 2021 | A1 |
| 20210244950 | Ironi et al. | Aug 2021 | A1 |
| 20210252278 | Hamner et al. | Aug 2021 | A1 |
| 20210260379 | Charlesworth et al. | Aug 2021 | A1 |
| 20210266011 | Chen et al. | Aug 2021 | A1 |
| 20210283400 | Hamner et al. | Sep 2021 | A1 |
| 20210289814 | Roubos-van den Hil et al. | Sep 2021 | A1 |
| 20210299445 | Rajguru et al. | Sep 2021 | A1 |
| 20210308460 | Wong et al. | Oct 2021 | A1 |
| 20210330547 | Moaddeb et al. | Oct 2021 | A1 |
| 20210330974 | Wong et al. | Oct 2021 | A1 |
| 20210353181 | Roh | Nov 2021 | A1 |
| 20210379374 | Hamner et al. | Dec 2021 | A1 |
| 20210379379 | Campean et al. | Dec 2021 | A1 |
| 20210402172 | Ross et al. | Dec 2021 | A1 |
| 20220001164 | Sharma et al. | Jan 2022 | A1 |
| 20220016413 | John et al. | Jan 2022 | A1 |
| 20220031245 | Bresler | Feb 2022 | A1 |
| 20220054820 | Turner | Feb 2022 | A1 |
| 20220054831 | McBride | Feb 2022 | A1 |
| 20220088373 | Burnett | Mar 2022 | A1 |
| 20220126095 | Rajguru et al. | Apr 2022 | A1 |
| 20220143391 | Vaishya et al. | May 2022 | A1 |
| 20220143392 | Labuschagne et al. | May 2022 | A1 |
| 20220143393 | Charlesworth et al. | May 2022 | A1 |
| 20220143402 | Oppenheim et al. | May 2022 | A1 |
| 20220203091 | Vysokov | Jun 2022 | A1 |
| 20220212007 | Rajguru et al. | Jul 2022 | A1 |
| 20220218991 | Moaddeb et al. | Jul 2022 | A1 |
| 20220220276 | Ziebell et al. | Jul 2022 | A1 |
| 20220233860 | Hamner et al. | Jul 2022 | A1 |
| 20220266011 | Hamner et al. | Aug 2022 | A1 |
| 20220266012 | Hamner et al. | Aug 2022 | A1 |
| 20220347461 | Campean et al. | Nov 2022 | A1 |
| 20220401721 | Jackson et al. | Dec 2022 | A1 |
| 20230009158 | Liberatore | Jan 2023 | A1 |
| 20230010696 | Pradeep | Jan 2023 | A1 |
| 20230062326 | Colachis et al. | Mar 2023 | A1 |
| 20230110185 | Mantovani et al. | Apr 2023 | A1 |
| 20230191115 | Blum et al. | Jun 2023 | A1 |
| 20230191126 | Kent et al. | Jun 2023 | A1 |
| 20230201584 | Rajguru et al. | Jun 2023 | A1 |
| 20230218897 | Wang et al. | Jul 2023 | A1 |
| 20230248962 | Zhang et al. | Aug 2023 | A1 |
| 20230277109 | Blum et al. | Sep 2023 | A1 |
| 20230277841 | Wang et al. | Sep 2023 | A1 |
| 20230285743 | Muccio | Sep 2023 | A1 |
| 20230293882 | Howe | Sep 2023 | A1 |
| 20230321430 | Ye et al. | Oct 2023 | A1 |
| 20230371846 | Sharma et al. | Nov 2023 | A1 |
| 20240058606 | Law et al. | Feb 2024 | A1 |
| 20240066286 | Yin et al. | Feb 2024 | A1 |
| 20240066287 | Siff | Feb 2024 | A1 |
| 20240090600 | Colachis et al. | Mar 2024 | A1 |
| 20240122797 | Moaddeb et al. | Apr 2024 | A1 |
| 20240123230 | Raghunathan | Apr 2024 | A1 |
| 20240157142 | Yeniel et al. | May 2024 | A1 |
| 20240189594 | Hamner et al. | Jun 2024 | A1 |
| 20240325727 | Hamner et al. | Oct 2024 | A1 |
| 20240325728 | Schulte et al. | Oct 2024 | A1 |
| Number | Date | Country |
|---|---|---|
| 1135722 | Nov 1996 | CN |
| 1547483 | Nov 2004 | CN |
| 1826154 | Aug 2006 | CN |
| 101022849 | Aug 2007 | CN |
| 101115524 | Jan 2008 | CN |
| 101365373 | Feb 2009 | CN |
| 101687093 | Mar 2010 | CN |
| 101801453 | Aug 2010 | CN |
| 102089031 | Jun 2011 | CN |
| 102481394 | May 2012 | CN |
| 202724457 | Feb 2013 | CN |
| 103517732 | Jan 2014 | CN |
| 103889503 | Jun 2014 | CN |
| 104144729 | Nov 2014 | CN |
| 104168951 | Nov 2014 | CN |
| 104519960 | Apr 2015 | CN |
| 105457158 | Apr 2016 | CN |
| 105848710 | Aug 2016 | CN |
| 106413805 | Feb 2017 | CN |
| 106687161 | May 2017 | CN |
| 106794347 | May 2017 | CN |
| 107949421 | Apr 2018 | CN |
| 108697890 | Oct 2018 | CN |
| 102008042373 | Apr 2010 | DE |
| 102009004011 | Jul 2010 | DE |
| 0 000 759 | Feb 1979 | EP |
| 0 725 665 | Jan 1998 | EP |
| 1 062 988 | Dec 2000 | EP |
| 1 558 333 | May 2007 | EP |
| 1 727 591 | Apr 2009 | EP |
| 2 383 014 | Nov 2011 | EP |
| 2 291 115 | Sep 2013 | EP |
| 2 801 389 | Nov 2014 | EP |
| 3 020 448 | May 2016 | EP |
| 2 029 222 | Mar 2017 | EP |
| 2 780 073 | Sep 2017 | EP |
| 1 951 365 | Oct 2017 | EP |
| 3 154 627 | Apr 2018 | EP |
| 2 827 771 | May 2018 | EP |
| 3 184 143 | Jul 2018 | EP |
| 3 075 412 | Dec 2018 | EP |
| 3 349 712 | Jul 2019 | EP |
| 3 503 960 | Mar 2020 | EP |
| 3 352 846 | Jul 2020 | EP |
| 3 493 874 | Aug 2020 | EP |
| 3 409 200 | Sep 2020 | EP |
| 3 427 793 | Nov 2020 | EP |
| 3758595 | Jan 2021 | EP |
| 3 641 876 | Apr 2021 | EP |
| 3 679 979 | Jun 2021 | EP |
| 3 402 404 | Jul 2021 | EP |
| 3 562 541 | Jul 2021 | EP |
| 3 675 795 | Aug 2021 | EP |
| 3 100 765 | Jan 2022 | EP |
| 3487578 | Dec 2022 | EP |
| 4108292 | Dec 2022 | EP |
| 3784337 | Jun 2023 | EP |
| 4233990 | Aug 2023 | EP |
| 3541279 | Sep 2023 | EP |
| 3463550 | Mar 2024 | EP |
| 3565631 | Apr 2024 | EP |
| 4356952 | Apr 2024 | EP |
| 3842094 | May 2024 | EP |
| 2222819 | Mar 2006 | ES |
| 2272137 | Jun 2008 | ES |
| 2496449 | May 2013 | GB |
| 2002-200178 | Jul 2002 | JP |
| 2003-501207 | Jan 2003 | JP |
| 2003-533299 | Nov 2003 | JP |
| 2004-512104 | Apr 2004 | JP |
| 2006-503658 | Feb 2006 | JP |
| 2008-018235 | Jan 2008 | JP |
| 2009-034328 | Feb 2009 | JP |
| 2009-512516 | Mar 2009 | JP |
| 2009-529352 | Aug 2009 | JP |
| 2010-506618 | Mar 2010 | JP |
| 2010-512926 | Apr 2010 | JP |
| 2010-246745 | Nov 2010 | JP |
| 2012-005596 | Jan 2012 | JP |
| 2012-055650 | Mar 2012 | JP |
| 2012-217565 | Nov 2012 | JP |
| 2013-017609 | Jan 2013 | JP |
| 2013-094305 | May 2013 | JP |
| 5439921 | Mar 2014 | JP |
| 2015-514460 | May 2015 | JP |
| 2016-511651 | Apr 2016 | JP |
| 2018-038597 | Mar 2018 | JP |
| 20130104446 | Sep 2013 | KR |
| WO 8701024 | Feb 1987 | WO |
| WO 94000187 | Jan 1994 | WO |
| WO 94017855 | Aug 1994 | WO |
| WO 96032909 | Oct 1996 | WO |
| WO 98043700 | Oct 1998 | WO |
| WO 99019019 | Apr 1999 | WO |
| WO 00015293 | Mar 2000 | WO |
| WO 00076436 | Dec 2000 | WO |
| WO 01087411 | Nov 2001 | WO |
| WO 02017987 | Mar 2002 | WO |
| WO 0234327 | May 2002 | WO |
| WO 2004037344 | May 2004 | WO |
| WO 2004108209 | Dec 2004 | WO |
| WO 2005007029 | May 2005 | WO |
| WO 05122894 | Dec 2005 | WO |
| WO 2006021820 | Mar 2006 | WO |
| WO 2006092007 | Sep 2006 | WO |
| WO 2006102724 | Oct 2006 | WO |
| WO 07092290 | Aug 2007 | WO |
| WO 2007092290 | Aug 2007 | WO |
| WO 07112092 | Oct 2007 | WO |
| WO 08045598 | Apr 2008 | WO |
| WO 08062395 | May 2008 | WO |
| WO 2008106174 | Sep 2008 | WO |
| WO 09153730 | Dec 2009 | WO |
| WO 2010014260 | Feb 2010 | WO |
| WO 10111321 | Sep 2010 | WO |
| WO 10141155 | Dec 2010 | WO |
| WO 11119224 | Sep 2011 | WO |
| WO 2011144883 | Nov 2011 | WO |
| WO 2011149656 | Dec 2011 | WO |
| WO 12040243 | Mar 2012 | WO |
| WO 13071307 | May 2013 | WO |
| WO 13074809 | May 2013 | WO |
| WO 13173727 | Nov 2013 | WO |
| WO 14043757 | Mar 2014 | WO |
| WO 14053041 | Apr 2014 | WO |
| WO 2014070999 | May 2014 | WO |
| WO 14089549 | Jun 2014 | WO |
| WO 14093964 | Jun 2014 | WO |
| WO 2014113813 | Jul 2014 | WO |
| WO 14146082 | Sep 2014 | WO |
| WO 14151431 | Sep 2014 | WO |
| WO 14153201 | Sep 2014 | WO |
| WO 14207512 | Dec 2014 | WO |
| WO 15033152 | Mar 2015 | WO |
| WO 15039206 | Mar 2015 | WO |
| WO 15039244 | Mar 2015 | WO |
| WO 15042365 | Mar 2015 | WO |
| WO 15079319 | Jun 2015 | WO |
| WO 15095880 | Jun 2015 | WO |
| WO 2015085880 | Jun 2015 | WO |
| WO 15128090 | Sep 2015 | WO |
| WO 15138981 | Sep 2015 | WO |
| WO 2015138981 | Sep 2015 | WO |
| WO 15164706 | Oct 2015 | WO |
| WO 2015187712 | Dec 2015 | WO |
| WO 16007093 | Jan 2016 | WO |
| WO 16019250 | Feb 2016 | WO |
| WO 16094728 | Jun 2016 | WO |
| WO 16102958 | Jun 2016 | WO |
| WO 16110804 | Jul 2016 | WO |
| WO 16128985 | Aug 2016 | WO |
| WO 16149751 | Sep 2016 | WO |
| WO 16166281 | Oct 2016 | WO |
| WO 16179407 | Nov 2016 | WO |
| WO 2016176668 | Nov 2016 | WO |
| WO 16189422 | Dec 2016 | WO |
| WO 16195587 | Dec 2016 | WO |
| WO 2016201366 | Dec 2016 | WO |
| WO 17004021 | Jan 2017 | WO |
| WO 17010930 | Jan 2017 | WO |
| WO 2017023864 | Feb 2017 | WO |
| WO 17044904 | Mar 2017 | WO |
| WO 2017053847 | Mar 2017 | WO |
| WO 17062994 | Apr 2017 | WO |
| WO 17086798 | May 2017 | WO |
| WO 17088573 | Jun 2017 | WO |
| WO 2017132067 | Aug 2017 | WO |
| WO 17199026 | Nov 2017 | WO |
| WO 17208167 | Dec 2017 | WO |
| WO 17209673 | Dec 2017 | WO |
| WO 17210729 | Dec 2017 | WO |
| WO 17221037 | Dec 2017 | WO |
| WO 2018009680 | Jan 2018 | WO |
| WO 18028170 | Feb 2018 | WO |
| WO 18028220 | Feb 2018 | WO |
| WO 18028221 | Feb 2018 | WO |
| WO 2018039458 | Mar 2018 | WO |
| WO 18093765 | May 2018 | WO |
| WO 18106839 | Jun 2018 | WO |
| WO 18112164 | Jun 2018 | WO |
| WO 2018106839 | Jun 2018 | WO |
| WO 2018119220 | Jun 2018 | WO |
| WO 2018187241 | Oct 2018 | WO |
| WO 19005774 | Jan 2019 | WO |
| WO 19014250 | Jan 2019 | WO |
| WO 19028000 | Feb 2019 | WO |
| WO 19046180 | Mar 2019 | WO |
| WO 19082180 | Jun 2019 | WO |
| WO 2019143790 | Jul 2019 | WO |
| WO 19169240 | Sep 2019 | WO |
| WO 19202489 | Oct 2019 | WO |
| WO 2019213433 | Nov 2019 | WO |
| WO 2020006048 | Jan 2020 | WO |
| WO 20068830 | Apr 2020 | WO |
| WO 2020069219 | Apr 2020 | WO |
| WO 2020086726 | Apr 2020 | WO |
| WO 20131857 | Jun 2020 | WO |
| WO 20185601 | Sep 2020 | WO |
| WO 21005584 | Jan 2021 | WO |
| WO 21055716 | Mar 2021 | WO |
| WO 21062345 | Apr 2021 | WO |
| WO 21127422 | Jun 2021 | WO |
| WO 21228128 | Nov 2021 | WO |
| WO 2021236815 | Nov 2021 | WO |
| WO 21252292 | Dec 2021 | WO |
| WO 2022090834 | May 2022 | WO |
| WO 2022221858 | Oct 2022 | WO |
| WO 2022235607 | Nov 2022 | WO |
| WO 2023283568 | Jan 2023 | WO |
| WO 2023014499 | Feb 2023 | WO |
| WO 2023015158 | Feb 2023 | WO |
| WO 2023015159 | Mar 2023 | WO |
| WO 2023156391 | Aug 2023 | WO |
| WO 2023163300 | Aug 2023 | WO |
| WO 2023191236 | Oct 2023 | WO |
| WO 2023196578 | Oct 2023 | WO |
| WO 2023222911 | Nov 2023 | WO |
| WO 2024083685 | Apr 2024 | WO |
| Entry |
|---|
| Apartis; Clinical neurophysiology in movement disorders. Handb Clin Neurol; 111; Pediatric Neurology Pt. 1; pp. 87-92;Apr. 2013. |
| Barath et al., 2020, Brain metabolic changes with longitudinal transcutaneous afferent patterned stimulation in essential tremor subjects, Tremor and Other Hyperkinetic Movements, 10(1):52, pp. 1-10. |
| Barbaud et al.; Improvement in essential tremor after pure sensory stroke due to thalamic infarction; European neurology; 46; pp. 57-59; Jul. 2001. |
| Barrios et al.: BCI algorithms for tremor identification, characterization and tracking; Seventh Framework Programme, EU; Contract No. FP7-ICT-2007-224051 (v3.0); 57 pgs.; Jul. 10, 2011. |
| Bartley et al.; Neuromodulation for overactive bladder; Nature Reviews Urology; 10; pp. 513-521; Sep. 2013. |
| Benabid et al.; A putative generalized model of the effects and mechanism of action of high frequency electrical stimulation of the central nervous system; Acta Neural Belg; 105(3); pp. 149-157; Sep. 2005. |
| Bergquist et al.: Motor unit recruitment when neuromuscular electrical stimulation is applied over a nerve trunk compared with a muscle belly: quadriceps femoris, Journal of Applied Physiology; vol. 113, No. 1, pp. 78-89; Jul. 2012. |
| Bergquist et al.; Motor unit recruitment when neuromuscular electrical stimulation is applied over a nerve trunk compared with a muscle belly: triceps surae, Journal of Applied Physiology; vol. 110, No. 3, pp. 627-637; Mar. 2011. |
| Bijelic et al.: E Actitrode®: The New Selective Stimulation Interface for Functional Movements in Hemiplegic Patients; Serbian Journal of Electrical Engineering; 1(3); pp. 21-28; Nov. 2004. |
| Birdno et al.; Pulse-to-pulse changes in the frequency of deep brain stimulation affect tremor and modeled neuronal activity.; Journal of Neurophysiology; 98; pp. 1675-1684; Jul. 2007. |
| Birdno et al.; Response of human thalamic neurons to high-frequency stimulation.; PloS One; 9(5); 10 pgs.; May 2014. |
| Birgersson et al.; Non-invasive bioimpedance of intact skin: mathematical modeling and experiments; Physiological Measurement; 32(1); pp. 1-18; Jan. 2011. |
| Bohling et al.; Comparison of the stratum corneum thickness measured in vivo with confocal Raman spectroscopy and confocal reflectance microscopy; Skin research and Technology; 20(1); pp. 50-47; Feb. 2014. |
| Bonaz, B., V. Sinniger, and S. Pellissier. “Vagus nerve stimulation: a new promising therapeutic tool in inflammatory bowel disease.” Journal of internal medicine 282.1 (2017): 46-63. |
| Bowman et al.; Effects of waveform parameters on comfort during transcutaneous neuromuscular electrical stimulation; Annals of Biomedical Engineering; 13(1); pp. 59-74; Jan. 1985. |
| Bratton et al.; Neural regulation of inflammation: no neural connection from the vagus to splenic sympathetic neurons; Exp Physiol 97.11 (2012); pp. 1180-1185. |
| Brillman et al., 2022, Real-world evidence of transcutaneous afferent patterned stimulation for essential tremor, Tremor and Other Hyperkinetic Movements, 12(1):27, pp. 1-11. |
| Brittain et al.; Tremor suppression by rhythmic transcranial current stimulation; Current Biology; 23; pp. 436-440; Mar. 2013. |
| Britton et al.; Modulation of postural tremors at the wrist by supramaximal electrical median nerve shocks in ET, PD, and normal subjects mimicking tremor; J Neurology, Neurosurgery, and Psychiatry; 56(10); pp. 1085-1089; Oct. 1993. |
| Buschbacher et al.; Manual of nerve conduction series; 2nd edition; Demos Medical Publishing, LLC; 2006. |
| Cagnan et al.; Phase dependent modulation of tremor amplitude in essential tremor through thalamic stimulation; Brain; 136(10); pp. 3062-3075; Oct. 2013. |
| Campero et al.; Peripheral projections of sensory fasicles in the human superificial radial nerve; Brain; 128(Pt 4); pp. 892-895; Apr. 2005. |
| Chen et al.; A web-based system for home monitoring of patients with Parkinson's disease using wearable sensors; IEEE Trans on Bio-Medical Engineering; 58(3); pp. 831-836; Mar. 2011. |
| Choi, Jong Bo, et al. “Analysis of heart rate variability in female patients with overactive bladder.” Urology 65.6 (2005): 1109-1112. |
| Clair et al.; Postactivation depression and recovery of reflex transmission during repetitive electrical stimulation of the human tibial nerve, Journal of Neurophysiology; vol. 106, No. 1; pp. 184-192; Jul. 2011. |
| Clar et al.; Skin impedance and moisturization; J. Soc. Cosmet. Chem.; 26; pp. 337-353; 1975; presented at IFSCC Vilith Int'l Congresson Cosmetics Quality and Safety in London on Aug. 26-30, 1974. |
| Constandinou et al.; A Partial-Current-Steering Biphasic Stimulation Driver for Vestibular Prostheses; IEEE Trans on Biomedical Circuits and Systems; 2(2); pp. 106-113; Jun. 2008. |
| Daneault et al.; Using a smart phone as a standalone platform for detection and monitoring of pathological tremors; Frontiers in Human Neuroscience; vol. 6, article 357; 12 pgs.; Jan. 2012. |
| Deuschl et at; Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee., Movement Disorders, vol. 13 Suppl 3, pp. 2-23; 1998. |
| Di Giovangiulio et al.; The Neuromodulation of the intestinal immune system and its relevance in inflammatory bowel disease; Fronteir's in Immunology; vol. 6; Article 590; Nov. 2015. |
| Dideriksen et al.; EMG-based characterization of pathological tremor using the iterated Hilbert transform; IEEE transactions on Bio-medical Engineering; 58(10); pp. 2911-2921; Oct. 2011. |
| Dosen et al.: Tremor suppression using electromyography and surface sensory electrical stimulation; Converging Clinical and Engineering Research on Neurorehabilitation; vol. 1 (Siosystems & Biorobotics Series); pp. 539-543; Feb. 2013. |
| Doucet et al.; Neuromuscular electrical stimulation for skeletal muscle function; The Yale Journal of Biology and Medicine; 85(2); pp. 201-215; Jun. 2012. |
| Ferreira et al., 2019, MDS evidence-based review of treatments for essential tremor, Movement Disorders, 34(7):950-958. |
| Fiorentino et al., 2011, Self calibrating wearable active running asummetry measurement and correction, Journal of Control Engineering and Applied Informatics, 13(2):3-8. |
| Fuentes et al.; Restoration of locomotive function in Parkinson's disease by spinal cord stimulation: mechanistic approach, Eur J Neurosci, vol. 32, pp. 1100-1108; Oct. 2010 (author manuscript; 19 pgs.). |
| Fuentes et al.; Spinal cord stimulation restores locomotion in animal models of Parkinson's disease; Science; 323; pp. 1578-1582; Mar. 2009. |
| Gallego et al.; A neuroprosthesis for tremor management through the control of muscle co-contraction; Journal of Neuroengineering and Rehabilitation; vol. 10; 36; (13 pgs); Apr. 2013. |
| Gallego et al.; Real-time estimation of pathological tremor parameters from gyroscope data.; Sensors; 10(3); pp. 2129-2149; Mar. 2010. |
| Gallego et al; A soft wearable robot for tremor assessment and suppression; 2011 IEEE International Conference on Robotics and Automation; Shanghai International Conference Center; pp. 2249-2254; May 9-13, 2011. |
| Gao; Analysis of amplitude and frequency variations of essential and Parkinsonian tremors; Medical & Biological Engineering & Computing; 42(3); pp. 345-349; May 2004. |
| Garcia et al.; Modulation of brainstem activity and connectivity by respiratory-gated auricular vagal afferent nerve stimulation in migraine patients; Pain; International Association for the Study of Pain; 2017. |
| Garcia-Rill, E., et al. “Arousal, motor control, and Parkinson's disease.” Translational neuroscience 6.1 pp. 198-207 (2015). |
| Giuffridda et al.; Clinically deployable Kinesia technology for automated tremor assessment.; Movement Disorders; 24(5); pp. 723-730; Apr. 2009. |
| Gracanin et al.; Optimal stimulus parameters for minimum pain in the chronic stimulatin of innervated muscle; Archives of Physical Medicine and Rehabilitation; 56(6); pp. 243-249; Jun. 1975. |
| Gupta et al., 2021, Exploring essential tremor: results from a large online survey, Clinical Parkinsonism & Related Disorders, 5:100101, 4 pp. |
| Haeri et al.; Modeling the Parkinson's tremor and its treatments; Journal of Theorectical Biology; 236(3); pp. 311-322; Oct. 2005. |
| Halonen et al.; Contribution of cutaneous and muscle afferent fibres to cortical SEPs following median and radial nerve stimulation in man; Electroenceph. Clin. Neurophysiol.; 71(5); pp. 331-335; Sep.-Oct. 1988. |
| Hao et al.; Effects of electrical stimulation of cutaneous afferents on corticospinal transmission of tremor signals in patients with Parkinson's disease; 6th International Conference on Neural Engineering; San Diego, CA; pp. 355-358; Nov. 2013. |
| Haubenberger et al., 2018, Essential Tremor, The New England Journal of Medicine, 378:1802-1810 and Supplementary Appendix. |
| Hauptmann et al.; External trial deep brain stimulation device for the application of desynchronizing stimulation techniques; Journal of Neural Engineering; 6; 12 pgs.; Oct. 2009. |
| Heller et al.; Automated setup of functional electrical stimulation for drop foot using a novel 64 channel prototype stimulator and electrode array: Results from a gait-lab based study; Medical Engineering & Physic; 35(1); pp. 74-81; Jan. 2013. |
| Hellwig et al., Feb. 17, 2001, Tremor-correlated cortical activity in essential tremor, The Lancet, 357:519-523. |
| Henry Dreyfuss Associates; The Measure of Man and Woman: Human Factors in Design (Revised Edition); John Wiley & Sons, New York; pp. 10-11 and 22-25; Dec. 2001. |
| Hernan, Miguel, et al. “Alcohol Consumption and the Incidence of Parkinson's Disease.” May 15, 2003. Annals of Neurology. vol. 54. pp. 170-175. |
| Hernandez-Martin et al., 2021, High-fidelity transmission of high-frequency burst stimuli from peripheral nerve to thalamic nuclei in children with dystonia, Scientific Reports, 11:8498, 9 pp. |
| Hua et al.; Posture-related oscillations in human cerebellar thalamus in essential tremor are enabled by voluntary motor circuits; J Neurophysiol; 93(1); pp. 117-127; Jan. 2005. |
| Huang, et al.; Theta burst stimulation report of the human motor cortex; Neuron, vol. 45, 201-206, Jan. 20, 2005. |
| Hubeaux, Katelyne, et al. “Autonomic nervous system activity during bladder filling assessed by heart rate variability analysis in women with idiopathic overactive bladder syndrome or stress urinary incontinence.” The Journal of urology 178.6 (2007): 2483-2487. |
| Hubeaux, Katelyne, et al. “Evidence for autonomic nervous system dysfunction in females with idiopathic overactive bladder syndrome.” Neurourology and urodynamics 30.8 (2011): 1467-1472. |
| Inoue et al. “Stretchable human interface using a conductive silicone elastomer containing silver fillers.” Consumer Electronics, 2009. ISCE'09. IEEE 13th International Symposium on. IEEE, 2009. |
| Isaacson et al., 2020, Prospective home-use study on non-invasive neuromodulation therapy for essential tremor, Tremor and Other Hyperkinetic Movements, 10(1):29, pp. 1-16. |
| Jacks et al.; Instability in human forearm movements studied with feed-back-controlled electrical stimulation of muscles; Journal of Physiology; 402; pp. 443-461; Aug. 1988. |
| Jobges et al.; Vibratory proprioceptive stimulation affects Parkinsonian tremor; Parkinsonism & Related Disorders; 8(3); pp. 171-176; Jan. 2002. |
| Joundi et al.; Rapid tremor frequency assessment with the iPhone accelerometer.; Parkinsonism & Related Disorders; 17(4); pp. 288-290; May 2011. |
| Kim et al.: Adaptive control of movement for neuromuscular stimulation-assisted therapy in a rodent model; IEEE Trans on Biomedical Engineering,; 56(2); pp. 452-461; Feb. 2009. |
| Krauss et al.; Chronic spinal cord stimulation in medically intractable orthostatic tremor; J Neurol Neurosurg Psychiatry; 77(9); pp. 1013-1016; Sep. 2006. |
| Krishnamoorthy et al., 2008, Gait Training After Stroke: A Pilot Study Combining a Gravity-Balanced Orthosis, Functional Electrical Stimulation, and Visual Feedback, Journal of Neurologic Physical Therapy, 32(4):192-202. |
| Kuhn et al.; Array electrode design for transcutaneous electrical stimulation a simulation study; Medical Engineering & Physics; 31 (8); pp. 945-951; Oct. 2009. |
| Kuhn et al.; The Influence of Electrode Size on Selectivity and Comfort in Transcutaneous Electrical Stimulation of the Forearm; Neural Systems and Rehabilitation Engineering, IEEE Transactions on; 18(3); pp. 255-262; Jun. 2010. |
| Kunz, Patrik, et al. “5 kHz transcranial alternating current stimulation: lack of cortical excitability changes when grouped in a theta burst pattern.” Frontiers in Human Neuroscience 10 (2016): 683. |
| Lagerquist et al.: Influence of stimulus pulse width on M-waves, H-reflexes, and torque during tetanic low-intensity neuromuscular stimulation, Muscle & Nerve, 42(6), pp. 886-893; Dec. 2010. |
| Laroy et al.; The sensory innervation pattern of the fingers; J. Neurol.; 245 (5); pp. 294-298; May 1998. |
| Lee et al.; Resetting of tremor by mechanical perturbations: A comparison of essential tremor and parkinsonian tremor; Annals of Nuerology; 10(6); pp. 523-531; Dec. 1981. |
| Legon et al.; Pulsed ultrasound differentially stimulates somatosensory circuits in humans as indicated by EEG and fMRI; PLoS ONE; 7(12); e51177; 14 pgs.; Dec. 2012. |
| Liao, Wen-Chien, et al. “A noninvasive evaluation of autonomic nervous system dysfunction in women with an overactive bladder.” International Journal of Gynecology & Obstetrics 110.1 (2010): 12-17. |
| Lin et al., 2018, Noninvasive neuromodulation inessential tremor demonstrates relief in a sham-controlled pilot trial, Movement Disorders, 33(7):1182-1183. |
| Llinas et al., Dec. 21, 1999, Thalamocortical dysrhythmia: a neurological and neuropsychiatric syndrome characterized by magnetoencephalography, PNAS, 96(26):15222-15227. |
| Lourenco et al.; Effects produced in human arm and forearm motoneurones after electrical stimulation of ulnar and median nerves at wrist level; Experimental Brain Research; 178(2); pp. 267-284; Apr. 2007. |
| Lyons et al., 2021, Essential tremor in adult patients, International Essential Tremor Foundation, 16 pp. |
| Malek et al.; The utility of electromyography and mechanomyography for assessing neuromuscular function: a noninvasive approach; Phys Med Rehabil in N Am; 23(1); pp. 23-32; Feb. 2012. |
| Mamorita et al.; Development of a system for measurement and analysis of tremor using a three-axis accelerometer; Methods Inf Med; 48(6); pp. 589-594; epub Nov. 2009. |
| Maneski et al.; Electrical Stimulation for suppression of pathological tremor; Med Biol Eng Comput; 49(10); pp. 1187-1193; Oct. 2011. |
| Marsden et al.; Coherence between cerebellar thalamus, cortex and muscle in man; Brain; 123; pp. 1459-1470; Jul. 2000. |
| Marshall, Ryan, et al. “Bioelectrical stimulation for the reduction of inflammation in inflammatory bowel disease.” Clinical Medicine Insights: Gastroenterology 8 (2015): CGast-S31779. |
| McAuley et al.; Physiological and pathological tremors and rhythmic central motor control; Brain; 123(Pt 8); pp. 1545-1567; Aug. 2000. |
| McIntyre et al.; Finite element analysis of current-density and electric field generated by metal microelectrodes; Annals of Biomedical Engineering; 29(3); pp. 227-235; Mar. 2001. |
| Meekins et al.; American Association of Neuromuscular & Electrodiagnostic Medicine evidenced-based review: use of surface electromyography in the diagnosis and study of neuromuscular disorders; Muscle Nerve 38(4); pp. 1219-1224; Oct. 2008. |
| Mehnert, Ulrich, et al. “Heart rate variability: an objective measure of autonomic activity and bladder sensations during urodynamics.” Neurourology and urodynamics 28.4 (2009): 313-319. |
| Miguel et al.; Alcohol consumption and the incidence of Parkinson's disease; Ann. Neurol.; 54(2); pp. 170-175; May 15, 2003. |
| Miller et al.; Multiplexed microneedle-based biosensor array for characterization of metabolic acidosis; Talanta; 88; pp. 739-742; Jan. 2012 (author manuscript; 13 pgs.). |
| Miller et al.; Neurostimulation in the treatment of primary headaches; Pract Neurol; Apr. 11, 2016;16:pp. 362-375. |
| Milne et al.; Habituation to repeated in painful and non-painful cutaneous stimuli: A quantitative psychophysical study; Experimental Brain Research; 87(2); pp. 438-444; Nov. 1991. |
| Mommaerts et al.; Excitation and nerve conduction; in Comprehensive Human Physiology; Springer Berlin Heidelberg; Chap. 13; pp. 283-294; Mar. 1996. |
| Mones et al.; The response of the tremor of patients with Parkinsonism to peripheral nerve stimulation; J Neurology, Neurosurgery, and Psychiatry; 32(6); pp. 512-518; Dec. 1969. |
| Morgante et al.: How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus?; Results of a Questionnaire, Partkinsonism Relat Disord; 13; pp. 528-531; Dec. 2007. |
| Munhoz et al; Acute effect of transcutaneous electrical nerve stimulation on tremor; Movement Disorders; 18(2); pp. 191-194; Feb. 2003. |
| Nardone et al.; Influences of transcutaneous electrical stimulation of cutaneous and mixed nerves on subcortical somatosensory evoked potentials; Electroenceph. Clin. Neurophysiol.; 74(1); pp. 24-35; Jan.-Feb. 1989. |
| Nonis et al.; Evidence of activation of vagal afferents by non-invasive vagus nerve stimulation: An electrophysiological study in healthy volunteers; Cephalalgia; pp. 1285-1293; vol. 37(13); Mar. 28, 2017. |
| Pahwa et al., 2018, An acute randomized controlled trial of noninvasive peripheral nerve stimulation in essential tremor, Neuromodulation, 22:537-545. |
| Peng et al., 2015, Flexible dry electrode based on carbon nanotube/plymer hybrid micorpillars for biopotential recording, Sensor and Actuatora A: Physical, 235:48-65. |
| Perez et al.; Patterned Sensory Stimulation Induces Plasticity in Reciprocal la Inhibition in Humans; The Journal of Neuroscience; 23(6); pp. 2014-2018; Mar. 2003. |
| Perez-Reyes, Jan. 2003, Molecular physiology of low-voltage-activated T-type calcium channels, Physiol. Rev. 83:117-161. |
| Perlmutter et al.; Deep brain stimulation; Ann Rev Neurosci; 29; pp. 229-257; Jul. 2006. |
| Popovic-Bijelic et al. “Multi-field surface electrode for selective electrical stimulation.” Artificial organs 29.6 (2005): 448-452. |
| Prochazka et al.; Attenuation of pathological tremors by functional electrical stimulation I: Method; Annals of Biomedical Engineering; 20(2); pp. 205-224; Mar. 1992. |
| Pulliam et al.; Continuous in-home monitoring of essential tremor; Parkinsonism Relat Disord; 20(1); pp. 37-40; Jan. 2014. |
| Quattrini et al.; Understanding the impact of painful diabetic neuropathy; Diabetes/Metabolism Research and Reviews; 19, Suppl. 1; pp. S2-S8; Jan.-Feb. 2003. |
| Rocon et al.; Design and validation of a rehabilitation robotic exoskeleton for tremor assessment and suppression; IEEE Trans Neural Sys and Rehab Eng.; 15(3); pp. 367-378; Sep. 2007. |
| Sigrist et al., 2012. Augmented visual, auditory, haptic, and multimodal feedback in motor learning: A review. Psychonomic Bulletin & Review, 20(1):21-53. |
| Silverstone et al.; Non-Invasive Neurostimulation in the Control of Familial Essential Tremor Using the Synaptic Neuromodulator; Conference Proceedings, International Functional Electrical Stimulation Society (IFES); Ed. Paul Meadows; 3 pgs.; May 1999. |
| Singer et al.; The effect of EMG triggered electrical stimulation plus task practice on arm function in chronic stroke patients with moderate-severe arm deficits; Restor Neurol Neurosci; 31(6); pp. 681-691; Oct. 2013. |
| Solomonow et al., 1998, Studies toward spasticity suppression with hight frequency electrical stimulation, Orthopedics, 7(8):1284-1288. |
| Straube et al.; Treatment of chronic migraine with transcutaneous stimulation of the auricular branch of the vagal nerve (auricular t-VNS): a randomized, monocentric clinical trial; The Journal of Headache and Pain (2015) 16:63. |
| Takanashi et al.; A functional MRI study of somatotopic representation of somatosensory stimulation in the cerebellum; Neuroradiology; 45(3); pp. 149-152; Mar. 2003. |
| Tass et al.; Coordinated reset has sustained aftereffects in Parkinsonian monkeys; Ann Neurol; 72(5); pp. 816-820; Nov. 2012. |
| Tass et al.; Counteracting tinnitus by acoustic coordinated reset neuromodulation; Restorative neurology and Neuroscience; 30(2); pp. 137-159; Apr. 2012. |
| Tass; A Model of desynchronizing deep brain stimulation with a demand-controlled coordinated reset of neural subpopulations; Bioi Cybern; 89(2); pp. 81-88; Aug. 2003. |
| Thomas et al.; A review of posterior tibial nerve stimulation for faecal incontinence; Colorectal Disease; 2012 The Association of Coloproctology of Great Britain and Ireland. 15, pp. 519-526; Jun. 25, 2012. |
| Tolosa et al.; Essential tremor: treatment with propranolol; Neurology; 25(11); pp. 1041; Nov. 1975. |
| Tracey; The inflammatory reflex; Nature; vol. 420; pp. 853-859; Dec. 19/26, 2002. |
| Treager; Interpretation of skin impedance measurements; Nature; 205; pp. 600-601; Feb. 1965. |
| Valente; Novel methods and circuits for field shaping in deep brain stimulation; Doctoral thesis, UCL (University College London); 222 pgs.; 2011. |
| Vitton et al.; Transcutaneous posterior tibial nerve stimulation for fecalIncontinence in inflammatory bowel disease patients: a therapeutic option?; Inflamm Bowel Dis; vol. 15, No. 3, Mar. 2009; pp. 402-405. |
| Von Lewinski et al.; Efficacy of EMG-triggered electrical arm stimulation in chronic hemiparetic stroke patients; Restor Neurol Neurosci; 27(3); pp. 189-197; Jun. 2009. |
| Wardman et al.; Subcortical, and cerebellar activation evoked by selective stimulation of muscle and cataneous afferents: an fMRI study; Physiol. Rep.; 2(4); pp. 1-16; Apr. 2014. |
| Wiestler et al.; Integration of sensory and motor representations of single fingers in the human; J. Neurophysiol.; 105(6); pp. 3042-3053; Jun. 2011. |
| Woldag et al.; Evidence-based physiotherapeutic concepts for improving arm and hand function in stroke patients R A review; J Neurol; 249(5); pp. 518-528; May 2002. |
| Woolf et al.; Peripheral nerve injury triggers central sprouting of myelinated afferents; Nature; 355(6355); pp. 75-78; Jan. 1992. |
| Yarnitsky et al.; Nonpainful remote electrical stimulation alleviates episodic migraine pain; Neurology 88; pp. 1250-1255; Mar. 28, 2017. |
| Yeh et al., “Intensity sensitive modulation effect of theta burst form of median nerve stimulation on the monosynaptic spinal reflex.” Neural plasticity 2015 (2015) in 8 pages. |
| Yilmaz, Ozlem O., et al. “Efficacy of EMG-biofeedback in knee osteoarthritis.” Rheumatology international 30.7 (2010): 887-892. |
| Zhang et al.; Neural oscillator based control for pathological tremor suppression via functional electrical stimulation; Control Engineering Practice; 19(1); pp. 74-88; Jan. 2011. |
| Zorba et al.; Overactive bladder and the pons; Rize University, Medical Faculty, Department of Urology; 123-124; Undated. |
| Zwarts et al.; Multichannel surface EMG: basic aspects and clinical utility; Muscle Nerve; 28(1); pp. 1-17; Jul. 2003. |
| Knutson et al., Nov. 2015, Neuromuscular electrical stimulation for motor restoration in hemiplegia, Phys. Med. Rehabil. Clin. N. Am., 26(4):729-745. |
| Amarenco et al. “Urondynamic Effect of Acute Transcutaneous Posterior Tibial Nerve Stimulation in Overactive Bladder” Journal of Urology vol. 169, 2210-2215 (Jun. 2003). |
| Buschbacher et al.; Manual of nerve conduction series; 2nd edition; Demos Medical Publishing, LLC; 2006 (part 2, p. #143 to #299). |
| Fred E. Govier, et al., “Percutaneous Afferent Neuromodulation for the Refractory Overactive Bladder: Results of a Multicenter Study,” 165 J. Urology 1193-1198 (Apr. 2001). |
| H.C. Klingler, et al., “Use of Peripheral Neuromodulation of the S3 Region for Treatment of Detrusor Overactivity: A Urodynamicbased Study,” Urology 56:766-771, 2000. |
| Knutson et al., Neuromuscular Electrical Stimulation for Motor Restoration in Hemiplegia. Phys Med Rehabil Clin N A,. Nov. 2015; 26(4): 729-745. Published online Aug. 14, 2015. Doi: 10.1016/j.pmr.2015.06.002. |
| Michael R. Van Balken, et al., “Posterior Tibial Nerve Stimulation as Neuromodulative Treatment of Lower Urinary Track Dysfunction,” 166 J. Urology 914-918 (Sep. 2001). |
| Popovi Maneski et al.; Electrical stimulation for the suppression of pathological tremor; Medical & Biological Engineering & Computing; 49(10); pp. 1187-1193; Oct. 2011. |
| Wallerberger, Apr. 4, 2019, Efficient Estimation of Autocorrelation Spectra, ArXiv.org, https://arxiv.org/abs/1810.05079. |
| Cala Trio Health Care Professional Guide (Jul. 2020). |
| Cala Trio Health Care Professional Guide (Nov. 2019). |
| Chang, M.D., Qwang-Yuen et al., Effect of Electroacupuncture and Transcutaneous Electrical Nerve Stimulation at Hegu (LI.4) Acupuncture Point on the Cutaneous Reflect, 27 Acupuncture & Electro-Therapeutics Res., Int. J. 191-202 (2002). |
| Javidan, et al, Attenuation of Pathological Tremors by Functional Electrical Stimulation II: Clinical Evaluation, 20 Annals of Biomedical Engineering 225 (1992). |
| PTAB-IPR2024-00732—Exhibit 1002—Declaration of John Laughlin, M. Eng., P.E., in 109 pages. |
| PTAB-IPR2024-00732—Petition for Inter Partes Review of U.S. Pat. No. 10,786,669, filed Mar. 29, 2024, in 101 pages. |
| PTAB-IPR2024-00743—Exhibit 1002—Declaration of John Laughlin, M. Eng., P.E., in 102 pages. |
| PTAB-IPR2024-00743—Petition for Inter Partes Review of U.S. Pat. No. 11,628,300, filed Mar. 29, 2024, in 113 pages. |
| Number | Date | Country | |
|---|---|---|---|
| 62886218 | Aug 2019 | US |